<SEC-DOCUMENT>0001683168-24-003246.txt : 20240513
<SEC-HEADER>0001683168-24-003246.hdr.sgml : 20240513
<ACCEPTANCE-DATETIME>20240510185856
ACCESSION NUMBER:		0001683168-24-003246
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240508
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240513
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		24936504

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:RDNT="http://radnet.com/20240508">
<head>
     <title>RadNet, Inc. 8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_RDNT_radnet.com_20240508 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240508_20240508 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0000790526 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000004" name="dei:EntityCentralIndexKey">0000790526</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rdnt-20240508.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-05-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000790526</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-08</xbrli:startDate>
        <xbrli:endDate>2024-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20240508__20240508_znpk7i4uT3Le"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported) <b><span id="xdx_90C_edei--DocumentPeriodEndDate_c20240508__20240508_zHn3nuGTMlYf"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May
8, 2024</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90B_edei--EntityRegistrantName_c20240508__20240508_zQMxW5D1xdB" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000011" name="dei:EntityRegistrantName">RadNet,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 32%"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20240508__20240508_z28ABsJtmmdb" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 32%"><span id="xdx_900_edei--EntityFileNumber_c20240508__20240508_zXTDOzSDkEE8" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000013" name="dei:EntityFileNumber">001-33307</ix:nonNumeric></b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 32%"><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20240508__20240508_zY3YilAiT6ba" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3326724</ix:nonNumeric></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction<br/>
    of incorporation)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 49%"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20240508__20240508_zSYb5e8eZOne"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000015" name="dei:EntityAddressAddressLine1">1510 Cotner Avenue</ix:nonNumeric></span></b></td>
  <td style="width: 2%">&#160;</td>
  <td style="text-align: center; width: 49%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; text-align: center"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20240508__20240508_zdiwbV4uThTi"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000016" name="dei:EntityAddressCityOrTown">Los
  Angeles</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240508__20240508_zdrvqtVomCy9"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: center"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20240508__20240508_zeubJw0jVB14"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000018" name="dei:EntityAddressPostalZipCode">90025</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center">(Address of Principal Executive Offices)</td>
  <td>&#160;</td>
  <td style="text-align: center">(Zip Code)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <b>(<span id="xdx_90A_edei--CityAreaCode_c20240508__20240508_zyFaV5N8egd5"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000019" name="dei:CityAreaCode">310</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20240508__20240508_zS5ED9s6BPV4"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000020" name="dei:LocalPhoneNumber">445-2800</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Registrant&#8217;s
Telephone Number, Including Area Code</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_90D_edei--WrittenCommunications_c20240508__20240508_zzGMuPesNDwa" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_90B_edei--SolicitingMaterial_c20240508__20240508_zRhJH68FNVH6" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_907_edei--PreCommencementTenderOffer_c20240508__20240508_zHTj1qDnrtPb" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20240508__20240508_zvRvL0S0yFth" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 35%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
                                            of each class</b></span></p></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span id="xdx_90B_edei--Security12bTitle_c20240508__20240508_z4qpagqQApHb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90C_edei--TradingSymbol_c20240508__20240508_z6op3NDszs4l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-05-08" id="Fact000026" name="dei:TradingSymbol">RDNT</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span id="xdx_90F_edei--SecurityExchangeName_c20240508__20240508_zh9SoDZA9irk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20240508__20240508_zCzhdTj2K80c"><ix:nonNumeric contextRef="AsOf2024-05-08" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in">Item 2.02</td><td>RESULTS OF OPERATIONS AND FINANCIAL CONDITION</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2024 RadNet, Inc.
(&#8220;RadNet&#8221;) issued a press release and, on May 9, 2024, held a conference call regarding its 2024 financial results for the
first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript of the conference
call is furnished as Exhibit 99.2 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this Current
Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report,
including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document filed
with the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS AND EXHIBITS</b></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
    <td style="width: 88%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>


<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-weight: normal"><a href="radnet_ex9901.htm">Press Release dated May 8, 2024 relating to RadNet, Inc.&#8217;s financial results for the quarter and full fiscal year ended March 31, 2024.</a></span></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>99.2</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-bottom: 0pt"><span style="font-weight: normal"><a href="radnet_ex9902.htm">Transcript of conference call.</a></span></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 99.1pt 0 98.85pt; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 10, 2024</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RADNET, INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 53%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 41%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark D.
    Stolper</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td/><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark  D. Stolper</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
    <td style="width: 88%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>


<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"><span style="font-weight: normal"><a href="radnet_ex9901.htm">Press Release dated May 8, 2024.</a></span></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>99.2</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"><span style="font-weight: normal"><a href="radnet_ex9902.htm">Transcript of conference call.</a></span></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fm2igvZNi4pYRYqIr8FuJdhmyyb+HclbGlvEZWFZZr4ZIXpiRUtTIcNpnmdwwLqptEfIsURGe8bgSNebBMLN8WKcZ219+/7AlAKDgRn3ldJBaK1347BIIB4N5GSgRiBlMpzCbCuir56SLU2B1htdgbYF7JkaNug1v7qEg36SpfrVVh2RnSGbgOzHnfwGFUsFO7rrB/HVQZalIuq1E4kV060JrsXTo/2SsKiwDnWuo/8bfQABzEqE -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_ex9901.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 8, 2024.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: red"><B><IMG SRC="image_002.jpg" ALT="" STYLE="height: 74.25pt; width: 172.5pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 14pt"><B>RadNet Reports First Quarter Financial
Results with Record First Quarter Revenue, Adjusted EBITDA<SUP>(1)</SUP> and Adjusted Earnings<SUP>(3)</SUP> and Revises Upwards 2024
Financial Guidance Ranges</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total Company Revenue increased 10.5% to $431.7 million in the first quarter
of 2024 from $390.6 million in the first quarter of 2023; Revenue from the Digital Health reportable segment increased 32.3% to $14.7
million in the first quarter of 2024 from $11.1 million in the first quarter of 2023</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Digital Health Revenue growth resulted in part from a $2.5 million (or
118.8%) increase in AI Revenue, which climbed to $4.7 million during the first quarter of 2024 from $2.1 million in the first quarter
of 2023</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext"><I>Total Company Adjusted EBITDA<SUP>(1) </SUP>was $58.5
million in the first quarter of 2024 as com</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">pared
with $48.2 million in the first quarter of 2023, an increase of 21.4%; </FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">Digital
Health reportable segment Adjusted EBITDA<SUP>(1)</SUP> increased to $3.5 million in the first quarter of 2024 from $20,000 in the first
quarter of 2023</FONT></I></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total Company Adjusted EBITDA<SUP>(1)</SUP> margins increased by 1.2%
to 13.5% in the first quarter of 2024 as compared with 12.3% in the first quarter of 2023</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><I>Adjusting for unusual or one-time items in the quarter,
Adjusted Diluted Earnings Per Share<SUP>(3)</SUP> was $0.07 for the first quarter of 2024; This compares with Adjusted Loss Per Share<SUP>(3)</SUP>
of $(0.22) for the first quarter of 2023 </I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aggregate procedural volumes increased 5.7% and same-center procedural
volumes increased 3.8% compared with the first quarter of 2023</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Completed the acquisition of Houston Medical Imaging on April 1<SUP>st</SUP>,
2024 and announced a second Houston acquisition of American Health Imaging centers, set to close during the second quarter of 2024</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RadNet revises full-year 2024 guidance levels to increase Revenue, Adjusted
EBITDA<SUP>(1)</SUP> and Free Cash Flow<SUP>(2)</SUP> ranges</I></FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LOS ANGELES, California, May 8, 2024 &ndash;
RadNet, Inc. (NASDAQ: RDNT),</B> <FONT STYLE="color: black">a national leader in providing high-quality, cost-effective, fixed-site outpatient
diagnostic imaging services through a network of 375 owned and operated outpatient imaging centers</FONT>, today reported financial results
for its first quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, &ldquo;Despite experiencing some adverse impact from severe winter weather conditions during the first quarter,
both the Imaging Center and newly established Digital Health reportable operating segments demonstrated strong growth and achieved first
quarter record results. Total Company Revenue grew 10.5% as compared with last year&rsquo;s first quarter to a record $431.7 million.
The Digital Health segment Revenue of $14.7 million increased 32.3% from last year&rsquo;s same quarter. The strong growth in Digital
Health was, in part, driven by our AI businesses, whose Revenue increased 118% as compared with last year&rsquo;s first quarter, mainly
on the continuing success of the rollout of our Enhanced Breast Cancer Detection (EBCD) DeepHealth AI-powered screening mammography program.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Improved reimbursement from commercial
and capitated payors, ongoing efforts toward greater operating efficiency and effective cost controls resulted in an increase to Adjusted
EBITDA<SUP>(1)</SUP> margins by 120 basis points over last year&rsquo;s first quarter. We believe there is further room for improvement,
especially as we continue to disproportionally grow the higher margin Digital Health businesses and lean into both clinical and generative
AI,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;At the end of the
first quarter, we announced a new joint venture in the northern and eastern parts of the San Fernando Valley of Los Angeles with Providence
Health System. As of quarter end, we had 137 of our 375 centers (or 36.5%) held in partnership with leading health systems. These partnerships
allow us to play a more integral role within the local healthcare communities we serve by increasing access, disseminating new technologies
and improving the quality of patient care.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Given the positive trends we are experiencing
in virtually all aspects of our business and the strong financial performance of the first quarter, we are revising upwards certain guidance
levels in anticipation of financial results that we believe will exceed our original expectations. Most significantly, we have increased
2024 guidance ranges for Revenue, Adjusted EBITDA<SUP>(1)</SUP> and Free Cash Flow<SUP>(2)</SUP>,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;We believe strong
growth is sustainable as we continue to execute on various initiatives. In response to high demand and patient backlogs in many of RadNet&rsquo;s
local markets, we embarked over a year ago on a program to expand capacity through the development and construction of new imaging centers.
We anticipate opening approximately a dozen new centers by year end 2024, and are working with prospective and existing health system
partners to expand joint venture offerings. Digital Health initiatives continue to expand, including the further rollout of the EBCD program
along with other clinical AI for lung and prostate cancers. Development of our DeepHealth OS technology platform is driving toward implementation
within RadNet beginning in the third quarter of this year and within external customers as early as the first quarter of 2025. This DeepHeatlh
OS will integrate new generative AI capabilities to help us and external customers automate and drive efficiencies for many of the back-office
and support functions involved with running imaging centers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;RadNet&rsquo;s balance sheet continues
to strengthen. In March, we completed an offering of common stock, where we raised net proceeds of approximately $219 million, which contributed
to the $527 million cash balance at quarter end. Additionally, subsequent to the quarter&rsquo;s end, we completed a successful debt refinancing
transaction, resulting in a reduction of our interest rates, an extension of maturities and the funding of additional cash to the balance
sheet of approximately $168 million. At quarter end, our leverage ratio of Net Debt to Adjusted EBITDA<SUP>(1)</SUP> was at a record low,
slightly above 1.0x,&rdquo; concluded Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2024, RadNet reported
Total Company Revenue of $431.7 million and Adjusted EBITDA<SUP>(1)</SUP> of $58.5 million. Revenue increased $41.1 million (or 10.5%)
and Adjusted EBITDA<SUP>(1)</SUP> increased $10.3 million (or 21.4%) as compared with the first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2024, RadNet reported
Imaging Center Revenue of $417.0 million and Adjusted EBITDA<SUP>(1)</SUP> of $54.9 million. Revenue increased $37.6 million (or 9.9%)
and Adjusted EBITDA<SUP>(1)</SUP> increased $6.8 million (or 14.1%) as compared with the first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2024, RadNet reported
Digital Health Revenue of $14.7 million and Adjusted EBITDA<SUP>(1)</SUP> of $3.5 million. Revenue increased $3.6 million (or 32.3%) and
Adjusted EBITDA<SUP>(1)</SUP> increased $3.5 million (or 17,500%) as compared with the first quarter of 2023. Digital Health Revenue and
Adjusted EBITDA<SUP>(1)</SUP> growth was due in part from a $2.5 million (or 118.8%) increase in AI Revenue, which climbed to $4.7 million
during the first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total Company Net Loss for the first quarter of
2024 was $2.8 million as compared with a Total Company Net Loss of $21.0 million for the first quarter of 2023. Net Loss Per Share <FONT STYLE="color: black">for
the first quarter of 2024 was $(0.04), compared with a Net Loss per share of $(0.36) in the first quarter of 2023, based upon a weighted
average number of diluted shares outstanding of 69.3 million shares in 2024 and 57.7 million shares in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">There were a number
of unusual or one-time items impacting the first quarter including: </FONT>$1.2 million of non-cash gain from interest rate swaps; <FONT STYLE="color: black">$1.0
million expense related to leases for our de novo facilities under construction that have yet to open their operations; $2.0 million non-cash
increase to contingent consideration related to completed acquisitions; and $3.3 million of non-capitalized research and development expenses
with respect to our DeepHealth Cloud OS and generative AI. Adjusting for the above items, Total Company Adjusted Earnings<SUP>(3)</SUP>
was $5.0 million and diluted Adjusted Earnings Per Share<SUP>(3)</SUP> was $0.07 during the first quarter of 2024. This compares with
Total Company Adjusted Loss<SUP>(3)</SUP> of $13.0 million and diluted Adjusted Loss Per Share<SUP>(3)</SUP> of $(0.22) during the first
quarter of 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2024, as compared with
the prior year&rsquo;s first quarter, MRI volume increased 11.7%, CT volume increased 9.1% and PET/CT volume increased 17.5%. Overall
volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 5.7% over the
prior year&rsquo;s first quarter. On a same-center basis, including only those centers which were part of RadNet for both the first quarters
of 2024 and 2023, MRI volume increased 9.9%, CT volume increased 6.5% and PET/CT volume increased 15.3%. Overall same-center volume, taking
into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 3.8% over the prior year&rsquo;s
same quarter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2024 Revised Guidance</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet amends its previously announced guidance
levels as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Imaging Center Segment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Original</U></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Guidance Range</U></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Revised</U></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Guidance Range</U></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: justify">Total Net Revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">$1,650 - $1,700 million</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">$1,675 - $1,725 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$250 - $260 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$255 - $265 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Capital Expenditures<SUP>(a)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$125 - $135 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$130 - $140 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Cash Interest Expense<SUP>(b)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$40 - $45 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$37 - $42 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Free Cash Flow<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$65 - $75 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$68 - $78 million</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Net of proceeds from the sale of equipment, imaging centers and joint venture interests and New Jersey
Imaging Network capital expenditures.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Includes payments to and from counterparties on interest rate swaps and nets interest income from our
cash balance recorded in Other Income.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Digital Health Segment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Original</U></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Guidance Range</U></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Revised</U></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Guidance Range</U></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: justify">Total Net Revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">$60 - $70 million</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">$60 - $70 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP> Before Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$12 - $14 million</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$13 - $15 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$11 - $13 million</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$12 - $14 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Capital Expenditures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$3 - $5 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$3 - $5 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Free Cash Flow<SUP>(2)</SUP> Before Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$8 - $10 million</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$8 - $10 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Free Cash Flow<SUP>(2)</SUP> After Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$(2) - $(5) million</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$(2) - $(5) million</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Financial Results Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its first quarter
2024 results on Thursday, May 9th, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conference Call Details:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Thursday, May 9, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 10:30 a.m. Eastern Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial In-Number: 844-826-3035</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Dial-In Number: 412-317-5195</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">It is recommended
that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and
archived webcasts available at </FONT>https://viavid.webcasts.com/starthere.jsp?ei=1667758&amp;tp_key=222b4e91a8 <FONT STYLE="font-size: 10pt">or
http://www.radnet.com under the &ldquo;Investors&rdquo; menu section and &ldquo;News Releases&rdquo; sub-menu of the website. An archived
replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international
callers, and using the passcode 10188629.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>About RadNet, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">RadNet, Inc. is the leading national provider
of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.
RadNet has a network of 375 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware,
New Jersey, New York, Florida, Texas and Arizona. In addition, RadNet provides radiology information technology and artificial intelligence
solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry.
Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over
9,700 employees. For more information, visit http://www.radnet.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified
by words such as: &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;goal,&rdquo; &ldquo;seek,&rdquo; &ldquo;believe,&rdquo;
&ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;likely,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and similar references to future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking statements include, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of a pandemic, significant deterioration
in the broader economy, severe acts of nature or other exogenous factors on our business, suppliers, payors, customers, referral sources,
partners, patients and employees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to service our indebtedness, make
principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our
ability to refinance such indebtedness on acceptable terms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in general economic conditions nationally
and regionally in the markets in which we operate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
the expansion of our business and improvements to our existing facilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain our current credit rating
and the impact on our funding costs and competitive position if we do not do so;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">our ability to acquire, develop, implement and monetize artificial intelligence
algorithms and applications;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">volatility in interest and exchange rates, or
credit markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the adequacy of our cash flow and earnings to
fund our current and future operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in service mix, revenue mix and procedure
volumes; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in receiving payments for services provided;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">increased bankruptcies among our partner physicians
or joint venture partners;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of the political environment and related
developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;
</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which the ongoing implementation
of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or
related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">closures or slowdowns and changes in labor costs
and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in
our facilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the occurrence of hostilities, political instability
or catastrophic events; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the emergence or reemergence of and effects related
to future pandemics, epidemics and infectious diseases; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">noncompliance by us with any privacy or security
laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized
use or disclosure of confidential information.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement contained in this
current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of
changed circumstances, new information, future developments or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation G: GAAP and Non-GAAP Financial
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains certain financial information
not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes
that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes
this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in
the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should
not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled
measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this
release in the tables which follow.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>CONTACTS: </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>RadNet, Inc.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mark Stolper, 310-445-2800</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Executive Vice President and Chief Financial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt"><BR>
</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 406.5pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Cash and Cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">526,980</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">342,570</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,707</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,342</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,007</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">47,657</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">795,828</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579,276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">618,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">604,401</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">621,612</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">596,032</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total property, plant, equipment and right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,240,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">694,292</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">679,463</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Other intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,483</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,643</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Investment in joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deposits and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,333</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,969,555</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,690,473</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND EQUITY</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable, accrued expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">324,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">342,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Due to affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,494</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,475</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,647</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Current operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,981</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Current portion of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">427,887</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">437,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Long-term operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">605,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">814,442</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">812,068</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred tax liability, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,776</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,074</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,721</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,892,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,877,114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EQUITY</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">RadNet, Inc. stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Common stock - $0.0001 par value, 200,000,000 shares authorized; 73,901,654 and 67,956,318 shares issued and outstanding at March&nbsp;31, 2024 and December&nbsp;31, 2023, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">969,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">722,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,943</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,484</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(82,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(79,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total RadNet, Inc.'s stockholders equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">872,955</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">204,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,664</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,077,325</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">813,359</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,969,555</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,690,473</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">REVENUE</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Service fee revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">397,189</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">352,420</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Revenue under capitation arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,518</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total service revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">431,707</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cost of operations, excluding depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">351,865</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss (gain) on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Severance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">225</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">420,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">383,893</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) FROM OPERATIONS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">11,339</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,671</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME AND EXPENSES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,267</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,324</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,428</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,216</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other expenses (income)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,934</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,432</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other expense (income)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,793</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,819</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) BEFORE INCOME TAXES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,546</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(13,148</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Benefit from (Provision for) income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,864</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,410</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(14,283</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss) attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,722</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,779</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(21,005</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">69,307,078</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57,701,439</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">69,307,078</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57,701,439</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Net income (loss)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">5,410</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(14,283</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net income to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of operating lease assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,711</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,699</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,324</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,428</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Distributions from joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(407</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization deferred financing costs and loan discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">746</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss (Gain) non sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of cash flow hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">922</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,216</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,897</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,335</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,865</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,997</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,277</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,691</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,726</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">942</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,883</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,080</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accounts payable, accrued expenses and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,839</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchase of imaging facilities and other acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,530</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,644</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchase of property and equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57,409</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,915</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60,937</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(65,556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Principal payments on notes and leases payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,102</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on Term Loan Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,875</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,688</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Contribution from noncontrolling partners</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of economic interests in majority owned subsidiary, net of taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from issuance of common stock upon exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">228,298</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,821</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(229</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,990</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">342,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127,834</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">526,980</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,844</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21,471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid during the period for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net income (loss) attributable to Radnet, Inc. common stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(2,779</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(21,005</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,864</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,267</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Severance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash employee stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,897</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">(Gain) loss on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,216</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Other (income) expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,934</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,432</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Non-cash change to contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non-operational rent expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,023</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">959</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA - Total Company</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">58,462</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,165</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjusted EBITDA - Digital Health Segment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA - Imaging Center Segment</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">54,942</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,145</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PAYOR CLASS BREAKDOWN</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 68%; text-align: left">Commercial Insurance</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: right">58.4%</TD><TD STYLE="width: 2%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">21.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Capitation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicaid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.5%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Workers Compensation/Personal Injury</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.7%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET PAYMENTS BY MODALITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Full Year</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%">MRI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">37.0%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">36.8%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">36.8%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">36.0%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16.5%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16.8%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">17.5%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">17.2%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.6%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.4%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.8%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.5%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>X-ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.3%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.5%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.7%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.9%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">13.6%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12.9%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12.6%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12.7%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16.4%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16.0%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">15.3%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16.1%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.9%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.8%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">0.9%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1.0%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.7%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.9%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.5%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.6%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PROCEDURES BY MODALITY*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">First Quarter</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 20%">MRI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">412,821</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 13%">369,556</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">250,365</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">229,379</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16,594</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">14,126</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8,595</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">9,258</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">639,221</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">608,986</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">472,514</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">455,479</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">X-ray and Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">846,841</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">817,851</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 20pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,646,951</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,504,635</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 180pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">* Volumes include wholly owned and joint venture centers. <BR>&nbsp; <BR>&nbsp; <BR> &nbsp; </P>




<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE <FONT STYLE="font: normal 700 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023 (iv)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><P STYLE="margin-top: 0; margin-bottom: 0">NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC.</P>
                                                                                <P STYLE="margin-left: 20pt; margin-top: 0; margin-bottom: 0">COMMON STOCKHOLDERS</P></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">(2,779</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">(21,005</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Subtract non-cash change in fair value of interest rate hedges (i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,216</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Legal Settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Non-operational rent expenses (iii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">959</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Holdback Re-valuation Adjustments - Quantib and Heart &amp; Lung Health</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">719</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left">Total adjustments - loss (gain)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,387</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Subtract tax impact of Adjustments (ii)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">637</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 30pt; text-align: left">Tax effected impact of adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,756</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,024</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0">TOTAL ADJUSTMENT TO NET INCOME (LOSS) ATTRIBUTABLE</P>
                                                                         <P STYLE="margin-left: 20pt; margin-top: 0; margin-bottom: 0">TO RADNET, INC. COMMON SHAREHOLDERS</P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,756</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,024</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><P STYLE="margin-top: 0; margin-bottom: 0"><B>ADJUSTED NET LOSS ATTRIBUTABLE TO RADNET, INC.</B></P>
                                                        <P STYLE="margin-left: 20pt; margin-top: 0; margin-bottom: 0"><B>COMMON STOCKHOLDERS</B></P></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,977</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,981</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><B>WEIGHTED AVERAGE SHARES OUTSTANDING</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,048,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,701,439</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><P STYLE="margin-top: 0; margin-bottom: 0">ADJUSTED DILUTED NET LOSS PER SHARE</P>
                                                                           <P STYLE="margin-left: 20pt; margin-top: 0; margin-bottom: 0">ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</P></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.07</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 5%">(i)</TD>
  <TD STYLE="text-align: justify; width: 95%">Impact from the change in fair value of the hedges during the quarter. Excludes the amortization of the accumulation of the changes in
fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">(ii)</TD>
  <TD STYLE="text-align: justify">Tax effected using - 8.63% and -52.5% blended federal and state effective tax rate for the first quarter of 2023 and 2024, respectively.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">(iii)</TD>
  <TD STYLE="text-align: justify">Represents rent expense associated with de novo sites under construction prior to them becoming operational.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">(iv)</TD>
  <TD STYLE="text-align: justify">Restated from what was presented in 2023 to include the losses of the AI businesses (ie, not add the losses back to earnings as was the
case in 2023). The restated Adjusted Earnings for 2023 is due to the fact that AI is no longer its own reportable operating segment and
is now embedded in the Digital Health reportable operating segment.</TD></TR>
</TABLE>




<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<U><BR STYLE="clear: both">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Footnotes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(1)</SUP>
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations
and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.
Adjusted EBITDA</FONT> includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries<FONT STYLE="color: windowtext">, and is adjusted for non-cash or extraordinary and one-time events taken place
during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA is reconciled to its nearest comparable
GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare
industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not
be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented,
may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(2)</SUP>
As noted above, the Company defines Free Cash Flow as </FONT>Adjusted EBITDA less total Capital Expenditures (whether completed with cash
or financed) and Cash Interest paid. <FONT STYLE="color: windowtext">Free Cash Flow is a non-GAAP financial measure. </FONT>The Company
uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity
to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows
generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free Cash Flow should not be considered a measure
of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives
to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the
consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined
in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable
to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(3)</SUP> The Company defines Adjusted Earnings
(Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of
equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation,
gain on extinguishment of debt, unusual or non-recurring entries that impact the Company&rsquo;s tax provision and any other non-recurring
or unusual transactions recorded during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted Earnings (Loss) Per Share is reconciled
to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical
indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered
a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share
is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as
presented, may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>radnet_ex9902.htm
<DESCRIPTION>TRANSCRIPT OF CONFERENCE CALL.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B><IMG SRC="image_068.jpg" ALT="" STYLE="height: 504px; width: 700px"></B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B><IMG SRC="image_071.jpg" ALT=""></B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00339A"><B>C O R P O R A
T E P A R T I C I P A N T S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger, </B><I>President, Chief Executive
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper, </B><I>Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00339A"><B>C O N F E R E
N C E C A L L P A R T I C I P A N T S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom, </B><I>Raymond James</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok, </B><I>Barclays</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Yuan Zhi, </B><I>B. Riley Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti, </B><I>Sidoti &amp; Co.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00339A"><B>P R E S E N T
A T I O N</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, everyone, and welcome to the RadNet
Inc. First Quarter 2024 Financial Results Conference Call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All participants will be in a listen-only mode.
Should you need assistance, please signal a conference specialist by pressing the star key, followed by zero. After today&rsquo;s presentation,
there will be an opportunity to ask questions. To ask a question, you may press star, then one using your touchtone telephone. To withdraw
your question, you may press star, then two. We also note today&rsquo;s event is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I&rsquo;d like to turn the floor
over to Mark Stolper, Executive Vice President and Chief Financial Officer. Sir, please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Good morning, ladies and gentlemen,
and thank you for joining Dr. Howard Berger and me today to discuss RadNet&rsquo;s first quarter 2024 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin today, we&rsquo;d like to remind
everyone of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated
future financial and operating performance, RadNet&rsquo;s ability to continue to grow the business by generating patient referrals and
contracts with radiology practices, recruiting and retaining technologists, receiving third party reimbursement for diagnostic imaging
services, successfully integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired operations as estimated,
among others, are forward-looking statements within the meaning of the Safe Harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on Management&rsquo;s
current preliminary expectations and are subject to risks and uncertainties which may cause RadNet&rsquo;s actual results to differ materially
from the statements contained herein. These risks and uncertainties include those risks set forth in RadNet&rsquo;s reports filed with
the SEC from time to time, including RadNet&rsquo;s annual report on Form 10-K for the year ended December 31, 2023. Undue reliance should
not be placed on forward-looking statements, especially guidance on future financial performance which speaks only as of the date it is
made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date they were made, or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I&rsquo;d like to turn the call over
to Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark. Good morning, everyone, and thank
you for joining us today. On today&rsquo;s call, Mark and I plan to provide you with highlights from our first quarter 2024 results, give
you more insight into factors which affected this performance, and discuss our future strategy. After our prepared remarks, we will open
the call to your questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d like to thank all of you for your interest
in our Company and for dedicating a portion of your day to participate in our conference this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let&rsquo;s begin. I am very pleased with our
performance in the first quarter. It was the strongest first quarter in our Company&rsquo;s history with record revenue, Adjusted EBITDA
and adjusted earnings. Relative to last year&rsquo;s first quarter, total Company revenue increased 10.5%, imaging center revenue increased
9.9%, and the new digital health revenue segment increased 32.3%. Imaging center revenue was driven by heavy demand in virtually all of
our markets despite being adversely impacted in the quarter on the east coast by several snowstorms and in California by unusual rainstorms
and flooding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevertheless, we continue to benefit from the
increasing utilization of diagnostic imaging within healthcare, as well as the shift of procedural volumes away from the more expensive
hospital alternatives to ambulatory freestanding centers like the ones we operate. Also contributing to the strong revenue performance
was the positive impact of improved reimbursement from commercial and capitated payors who recognize the important role we are playing
as a lower priced alternative to hospital-based imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, our top line is benefiting from the continuing
shift in modality mix towards advanced imaging, MR, CT and PET CT, where the revenue per scan is substantially higher than the routine
imaging. This is both a function of an overall industry trend as well as the significant capital investment we have made in the last few
years in advanced imaging equipment for growth and upgrades.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Driving the revenue growth within the digital
health was the AI business, including our EBCD - Enhanced Breast Cancer Detection breast cancer screening AI-powered initiative, which
grew 118.8% quarter over last year&rsquo;s same quarter. Adjusted EBITDA was also a first quarter record. In conjunction with the strong
revenue results which I just discussed, our focus on operational efficiency, improved management and utilization of labor, investments
in information technology and effective cost control contributed to a total Company Adjusted EBITDA which increased 21.4% from last year&rsquo;s
first quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another contributing factor to Adjusted EBITDA
growth was the disproportionate growth in the higher profit margin digital health segment businesses. Cumulatively, these factors drove
a 120 basis point increase in our Adjusted EBITDA margin as compared with last year&rsquo;s first quarter. While we are pleased with this
margin expansion, I remain convinced we have further opportunity to improve margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The strong operating results in the first quarter
relative to our internal budget, combined with ongoing operating trends that have continued into the second quarter resulted in our decision
to increase 2024 full year guidance ranges for revenue, Adjusted EBITDA, and free cash flow. Mark will discuss this in more detail in
his prepared remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue a multi-faceted approach to accelerate
our growth. With respect to acquisitions, some of you may have seen our two recent announcements regarding our entry into the Houston,
Texas market. Upon quarter end, we completed the acquisition of the seven imaging centers of Houston Medical Imaging. In addition, we
announced a second acquisition in April of six American Health imaging centers to be completed in June. Texas is the first new state we
have entered since 2020. The Houston metropolitan marketplace, encompassing about 7.3 million people, is the fourth most populous city
and the second fastest growing metropolitan area in the United States. We are confident of the opportunity for further acquisitions, de
novo build-outs as desirable, health system partnerships, and other means of expansion which include bringing our artificial intelligence
and leading edge clinical and operating digital health solutions to the patients and referring communities of greater Houston.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also during the first quarter, we completed a
tuck-in acquisition of four centers in the Antelope Valley, north of Los Angeles. New market acquisitions like Houston and the in-market
tuck-in acquisitions like that in Antelope Valley will be a continuing part of our growth strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Twenty-twenty-four will be a year of reinvestment
in our business to accelerate future growth. We currently have 12 de novo facilities in various stages of development which will open
for operations throughout the remainder of the year. These are on top of the two de novos which opened in the first quarter. These facilities
are located in markets where we have patient backlogs, require additional capacity, or where we currently lack access points to service
particular patient populations. While these projects are requiring us to make capital investments above our normal spending, we are confident
that these centers will be material contributors to our long term performance and growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to grow our hospital and health system
joint venture businesses. Currently, 137 of our 375 centers, or 36.5% are held within health system partnerships. Our partners are some
of the largest and most successful systems in our geographies. Partners include RWJBarnabas in New Jersey, Memorial Care, Dignity Health,
Lifebridge, University of Maryland, Advantis, Cedars Sinai, and others. These and other systems are seeking solutions for long term strategy
around outpatient imaging and have recognized that cost effective and efficient freestanding centers will continue to capture share from
hospitals as payors and patients alter their site of care towards lower cost, high quality facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our hospital and health system partners have been
instrumental in increasing our procedural volumes with their physician relationships. During the first quarter, we added seven additional
centers to our joint venture with Dignity Health in Arizona through the acquisition of facilities which were previously owned by Cigna&rsquo;s
Evernorth Care Group, and upon quarter close, we formed a new seven-center joint venture with Providence Health System in the northern
and eastern San Fernando Valley of Los Angeles. Furthermore, our Dignity joint venture in Ventura County recently acquired four imaging
centers in Oxnar and Ventura. Including these joint venture expansions and others upon which we are working, we expect to have close to
40% of our centers held within health system partnerships by year end 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to make progress in the digital health
segment. As some of you remember, we announced earlier this year the formation of the RadNet digital health financial reporting segment,
effective January 1, 2024, which combined the eRAD and DeepHealth operating system software businesses into what was our clinical AI reporting
segment in 2023. The financial impact of these digital health businesses has great potential for RadNet, both as a customer of the DeepHealth
OS and AI solutions, and of course as the owner of these businesses which sell their solutions to customers outside of RadNet. Software
businesses, in particular SaaS-based models can operate at significantly higher margin than RadNet&rsquo;s core imaging center segment
and require less capital investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within digital health, we continue to sell, service
and support eRAD solutions to new and existing customers while we focus on the ongoing development of the next generation DeepHealth OS
cloud-based operating system and generative AI modules. We continue to believe that DeepHealth OS could have a major impact in lowering
cost and increasing efficiency in the areas of patient scheduling, preauthorization, insurance verification, reporting, revenue cycle
management, and analytics. We will begin testing some of the AI-enabled automation tools of the DeepHealth OS in the third and fourth
quarters of this year and aim to have commercially available solutions in the first half of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enhanced breast cancer diagnostic mammography
offering continues its rollout in central and northern California. We expect implementation to be substantially complete as early as the
end of the second quarter. Adoption rates continue to rise in the east coast and are now approaching 40%. While the implementation in
southern California is more recent, we are encouraged from initial adoption rates, which are significantly higher than those experienced
at the beginning of the east coast rollout. Aidence Lung and Quantive Prostate and Neural AI Solutions are also expanding their customer
base, predominantly in Europe. This has been highlighted in the United Kingdom, where Aidence is the partner of choice for the full country
rollout of the NHS targeted lung health check lung cancer screening program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, we continue to improve liquidity and
financial leverage. We ended the first quarter with a cash balance of $527 million and a net debt to adjusted ratio of slightly more than
one time. Included in that cash balance were approximately $219 million of net proceeds from a successful stock offering we completed
in March. Additionally, subsequent to the end of the first quarter and completed on April 18, we opportunistically refinanced our debt
facilities. With this financing, we were able to reduce our cost of capital, extend maturities, and add an additional approximately $168
million to RadNet&rsquo;s cash balance. With all of this, RadNet is in the best financial condition in its history and is poised for accelerated
growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I&rsquo;d like to turn the call
back over to Mark to discuss some of the highlights of our first quarter 2024 performance. When he is finished, I will make some closing
remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Howard. I&rsquo;m now going to briefly
review our first quarter 2024 performance and attempt to highlight what I believe to be some material items. I will also give some further
explanation of certain items in our financial statements as well as provide some insights into some of the metrics that drove our first
quarter performance. I will also provide an update to 2024 financial guidance levels which were released in conjunction with our 2023
year-end results in March.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my discussion, I will use the term Adjusted
EBITDA, which is a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and
amortization, and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, and non-cash
equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests and subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period. A full quantitative
reconciliation of Adjusted EBITDA to net income or loss attributable to RadNet Inc. common stockholders is included in our earnings release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that said, I&rsquo;d now like to review our
first quarter 2024 results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2024, RadNet reported
total Company revenue of $431.7 million and Adjusted EBITDA of $58.5 million. Revenue increased $41.1 million or 10.5% and Adjusted EBITDA
increased $10.3 million or 21.4% as compared with the first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Breaking this performance down to the individual
operating segments, our imaging center segment reported revenue of $417 million and Adjusted EBITDA of $54.9 million. This was an increase
of $37.6 million or 9.9% in revenue and an increase of $6.8 million or 14.1% in Adjusted EBITDA as compared with last year&rsquo;s first
quarter. Driving this performance were strong aggregate and same center procedural volumes, the impact of higher reimbursement we are
receiving from commercial and capitated payors, the gradual movement towards advanced imaging, and tight expense control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The digital health segment reported revenue of
$14.7 million and Adjusted EBITDA of $3.5 million during the quarter. Revenue increased $3.6 million or 32.3% and Adjusted EBITDA increased
$3.5 million or 17,500% as compared with the first quarter of 2023. Digital health&rsquo;s significant growth was due in part to a $2.5
million or 118.8% increase in AI revenue, which climbed to $4.7 million during the first quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total Company net loss for the first quarter of
2024 was $2.8 million as compared with a total Company net loss of $21 million for the first quarter of 2023. Net loss per share for the
first quarter of 2024 was negative $0.04 compared with a net loss per share of negative $0.36 in the first quarter of 2023, based upon
a weighted average number of diluted shares outstanding of 69.3 million shares in 2024 and 57.7 million shares in 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were a number of unusual or one-time items
impacting the first quarter, including the following: $1.2 million of non-cash gain from interest rate swaps, $1 million expense related
to leases for our de novo facilities under construction that have not yet opened for operations, $2 million non-cash increase to contingent
consideration related to completed acquisitions, and $3.3 million of non-capitalized research and development expenses with respect to
our new DeepHealth cloud OS and generative AI. Adjusting for the above items, total Company adjusted earnings was $5 million for the quarter
and diluted adjusted earnings per share was $0.07 per share during the first quarter of 2024. This compares with total Company adjusted
loss of $13 million and diluted adjusted loss per share of negative $0.22 during the first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2024 as compared with
the prior year&rsquo;s first quarter, MRI volume increased 11.7%, CT volume increased 9.1%, and PET CT volume increased 17.5%. Overall
volume, taking into account routine imaging exams inclusive of X-ray, ultrasound, mammography, and all other exams increased 5.7% over
the prior year&rsquo;s first quarter. On a same center basis including only those centers which were part of RadNet for both the first
quarters of 2024 and 2023, MRI volume increased 9.9%, CT volume increased 6.5%, and PET CT volume increased 15.3%. Overall same center
volume, taking into account all routine imaging exams, increased 3.8% over the prior year same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the first quarter of 2024, we performed 2,646,951
total procedures. The procedures were consistent with our multi-modality approach whereby 74.3% of all the work we did by volume was from
routine imaging. Since we now have a table of our aggregate procedure volumes broken down by modality in our earnings release, I won&rsquo;t
go through the numbers, but want to make the following point. In his remarks, Dr. Berger mentioned that we are experiencing a slow shift
to higher acuity procedures, or what we call advanced imaging. In the first quarter of this year, 25.7% of our procedures were from MRI,
CT and PET CT. In last year&rsquo;s first quarter, this metric was 24.5%, a shift of 1.2% of our procedure volumes towards advanced imaging.
With higher pricing and better margins, more advanced imaging improves our financial results, including our operating margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall, GAAP interest expense for the first quarter
of 2024 was $16.3 million as compared with $15.7 million during last year&rsquo;s first quarter. In the first quarter of 2024, cash interest
expense, which includes payments to and from counterparties on our interest rate swaps and net interest income from our cash balance,
was $10.5 million. This compares with $17.5 million in the first quarter of 2023. The lower cash interest expense this quarter is primarily
the result of more interest income on larger cash balances, as well as the timing of cash interest paid on our term loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to our balance sheet, as of March
31, 2024 unadjusted for bond to term loan discounts, we had $317.1 million of net debt, which is our total debt at par value less our
cash balance. This compares with $789.2 million of net debt at March 31, 2023. Note that this debt balance includes New Jersey imaging
network debt of $142.5 million, for which RadNet is neither a borrower nor guarantor. As of March 31, 2024, we were undrawn on our $195
million line of credit and had a cash balance of $527 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2024, our accounts receivable balance
was $189.6 million, an increase of $25.9 million from year end 2023. The increase in accounts receivable is primarily the result of some
collection delays resulting from the cyber attack on Change Healthcare and the normal first quarter effect of cash collections from the
resetting of patient deductibles each year in January. Despite the impact from the Change Healthcare breach, our DSOs, or days sales outstanding,
was 34.9 days at March 31, 2024, near a historic low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through March 31, 2024, we had total capital expenditures
net of proceeds from the sale of imaging equipment of $64.4 million. This total includes $6.9 million spent under equipment notes and
the remainder spent in cash. Note that each year, we front-load the majority of our capital decisions into the first part of the year
and have been spending extraordinarily on growth CapEx to fund the 12 de novo facilities in construction, which are scheduled to open
before year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I&rsquo;d like to update and revise
our 2024 financial year guidance levels, which we released in conjunction with our fourth quarter and year-end 2023 results. Given the
positive trends we are experiencing in virtually all aspects of our business and the strong financial performance of the first quarter,
which is continuing into the second quarter, we are revising upwards certain guidance levels in anticipation of financial results that
we believe will exceed our original expectations for 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For revenue, we increased our guidance level for
the imaging center segment by $25 million, both at the low end and the top end of the range. Also for the imaging center segment, we&rsquo;ve
increased our EBITDA guidance by $5 million at the low end and the high end of our range. Our guidance level is now $255 million to $265
million. For capital expenditures for the imaging center segment, we increased our guidance both at the low end and the high end of the
range by $5 million. For cash paid for interest, due to the refinancing transaction and our much larger cash balance, we&rsquo;ve decreased
our cash paid for interest this year by $3 million, both at the low end and the high end of the range, and anticipate our cash interest
expense to be $37 million to $42 million, and we increased our free cash flow generation guidance level by $3 million to $68 million to
$78 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the digital health segment, we increased our
EBITDA guidance by $1 million both at the low end and the high end of the range to $13 million to $15 million. We increased our non-capitalized
R&amp;D expenditures by $1 million to $12 million to $14 million, and all other guidance ranges remain the same for the digital health
platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll now discuss reimbursement with respect
to Medicare. With respect to Medicare reimbursement for 2025, there is nothing to report at this time. As is typical each year, we are
expecting CMS to release a preliminary rate schedule sometime in June or July, at which time we will analyze CMS&rsquo; proposal and our
industry&rsquo;s lobbying groups will provide CMS our industry&rsquo;s feedback. At the time of our second quarter financial results call,
we will be in a position to comment on CMS&rsquo; proposal and its impact, if any, upon RadNet&rsquo;s future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, we did receive some good news in March
regarding 2024 Medicare rates. Effective March 9 of this year as part of the Consolidated Appropriations Act, 1.72% of the 3.4% scheduled
reduction in the conversion factor of the 2024 Medicare fee schedule was eliminated on a prospective basis. The reduction of the cut applies
to all of our Medicare billings from March 9 through the end of this year. As some of you may remember, the original proposed cut was
going to reduce our 2024 revenue by an estimated $7 million to $8 million, thus the mitigation gives back almost half of this amount,
thereby increasing our 2024 revenue by $3.4 million relative to our original expectations and budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this point, I&rsquo;d like to turn the call
back to Dr. Berger, who will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we move towards the half-year point of 2024,
we are excited about the initiatives we have for the remainder of the year. We are particularly encouraged by the progress we are making
in digital health. As we continue to improve and accelerate growth in the core imaging center business, our digital health initiatives
are poised to help us drive more revenue, reduce costs, and increase margins. We remain convinced that the successful future of any imaging
business will be heavily dependent upon the automation and efficiency by which patients and clinical data is managed, analyzed and processed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is the driver for our development of the
new DeepHealth OS, which will be the delivery platform for solutions which automate business processes and more effectively manage patient
and clinical data. We expect DeepHealth OS to further automate processes that today principally rely on human labor in the areas of patient
scheduling, clinical reporting, medical coding, sales and marketing, workflow improvement and analytics. In this vein, we are currently
making investments in foundation generative AI models. It is faster and less expensive for data scientists to use pre-trained foundation
models to develop new machine learning applications rather than train unique machine learning models from the ground up. When trained
on broad data sets, these models can support a diverse range of use cases, tasks that foundation models can perform, including language
processing, visual comprehension, code generation and human decision making. Advances in available foundation models will enable us to
design and test AI solutions more quickly and at a lower cost, giving us a distinct advantage when applied to the enormous database of
clinical and business information we own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we develop DeepHealth OS, we continue to
grow revenue from our clinical AI solutions for breast, lung and prostate cancer screening. Our objective is to design and deploy these
tools and others that lower the cost and increase the accuracy of cancer diagnosis in a form that can be packaged to create widespread
population health initiatives and screening. Our breast cancer AI and the EBCD program exemplifies this opportunity. Our breast AI is
improving the productivity and accuracy of our radiologists while providing a valuable benefit to our patients for which they are willing
to self pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are formulating similar screening programs
for prostate, lung and other chronic diseases for both domestic and international markets, as we firmly believe that healthcare needs
to shift towards prevention and early detection and not just focus on treating patients who are already sick. We look forward to updating
you further on the progress of our digital health initiatives in the coming quarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operator, we are now ready for the question-and-answer
portion of the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and gentlemen, at this time we&rsquo;ll
begin the question-and-answer session. To ask a question, you may press star, and then one using a touchtone telephone. To withdraw your
question, you may press star, and two. If you are using a speakerphone, we do ask that you please pick up the handset prior to pressing
the keys to ensure the best sound quality. Once again, that is star, and then one to join the question queue. We&rsquo;ll pause momentarily
to assemble the roster.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first question today comes from Brian Tanquilut
from Jefferies. Please go ahead with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning guys. Congrats on a really,
really strong quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maybe my first question, just given the strength
that we&rsquo;re seeing here, curious, Mark or Howard, what you are seeing in terms of the continued strength maybe into the quarter.
I know, Mark, that you alluded to that a little bit, but also pricing seems strong, so maybe if you can share with us any color on the
pricing strength as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Brian, thank you for your question.
In regards to pricing, we have, over the past several years, tried to transform at least RadNet from being what we have traditionally
called ourselves, price takers, to at least the opportunity to sit down and negotiate pricing with the various payors, other than Medicare,
of course, and Medicaid. But this past year and starting out in 2024, we&rsquo;ve taken a position, particularly given the enormous demand
that we have in backlogs, that contracts as they come up for renewal need to be at pricing levels that we think are appropriate, not only
for maintaining and sustaining the health of our Company and for the benefit of our patients and referring physicians, but take into account
increasing costs, primarily for labor, that we have been incurring now for the past couple of years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When we&rsquo;re not able to reach an agreement
as to what we believe are fair and sustainable rates, there are particular examples that I can give you with our capitation contracts,
we&rsquo;re prepared to go to fee-for-service, and which effectively did happen over the latter part of last year and beginning of this
year, where at least two of our contracts have moved to fee-for-service at rates substantially higher than what we were able to agree
for renewing the contracts if we stayed with capitation. I think this is really a function of finally being in a position where we&rsquo;re
not just going to accept pricing from any payor that isn&rsquo;t consistent with the appropriate business models and need for us not only
to cover increasing cost, but as you can see from our investment through our CapEx and building of de novo centers, a significant commitment
that we have to improving access and improving the state of the art technology by which we pride ourselves as being top of the industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think both of those have resonated well. We
are successful virtually in all of our negotiations, and I think that has contributed in part to the improved margins that Mark discussed
in his remarks. I think this will be a continuing effort on our part to continually monitor not only what the appropriate rates are but
also the tools by which we and everybody else in healthcare are burdened by, once we do a procedure, collecting those procedures. Our
revenue cycle management group as well as the contracting groups work hand in hand as we come up with these contract renewals to make
certain that we get paid for every procedure that we do and at rates that we think are not only consistent with our needs, but still remain
far lower than the alternative in many of our markets for hospital-based work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Then Howard, maybe just on the volume, just your
expectation for the continuation of the strength you&rsquo;re seeing there.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, well I think that&rsquo;s perhaps one of
the hidden milestones in our reporting here, Brian. There is clearly a trend towards using more advanced imaging as both the technology
improves and as the marketplace realizes the benefits and begins to adopt these. A 1.2% increase in our overall procedural volume shifting
from routine imaging to advanced imaging has been a remarkable achievement to demonstrate this.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In particular, I would like to point out the enormous
increase that we&rsquo;ve seen and which we will continue to accelerate, is PET CT. As I&rsquo;ve discussed on previous remarks and closed
calls, we are the largest providers now of what they call PSMA - PET CT scanning, which has been transformative for the diagnosis and
treatment of prostate cancer and is a substantial component of the almost, I believe it was 15% same store increase in PET CT scanning
between 2023 and first quarter of 2024. That, we think will continue to accelerate as this becomes more and more adopted by not only the
neurologic community but others who oversee the treatment of prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I also think that we may eventually in the latter
part of this year see a similar increase in PET CT scanning, as well as MR scanning from the new Alzheimer&rsquo;s drugs that have now
been approved, but which require both PET CT scanning and ongoing MRI scanning for monitoring. At this point, I think in the first quarter,
we&rsquo;ve done about 300 of these exams on a national scale with backlogs and demand for far more than that as more and more people
not only become aware of this, but as the criteria for doing these become more adopted and accessible to make certain that the patients
get reimbursed adequately&mdash;or appropriately, I should say, from the various payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trends that I think we&rsquo;re seeing in
imaging, particularly advanced imaging, will continue. We hope to also continue a shift into cardiac imaging and preventative cardiovascular
disease that we will be investing more time and human resources in, to building up for a procedure for screening for cardiac disease which
I believe will be a standard as far as population health and cardiovascular screening, probably in the very near future and for which
imaging is the poster child to managing good care and good outcomes. I expect advanced imaging to also benefit from the technology improvements
which are allowing us to do better throughout on our existing systems which we can&rsquo;t upgrade, or new systems where the processing
time or scanning time has been reduced significantly, and which allows us to facilitate and handle some of our backlog, which is another
reason why we&rsquo;re increasing our advanced imaging business. I think we&rsquo;ll be very happy to update you on our progress in all
these regards in our second and subsequent quarters of this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome, and then maybe just a follow-up question
for Mark. How are you thinking about balancing the spend on CapEx between maintenance CapEx and growth CapEx? Just curious what your philosophy
is there at this point. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, thanks for the question, Brian. That philosophy
changes year by year, depending upon what&rsquo;s on our plate; but what I would tell you is that this year, we&rsquo;re projecting upwards
of about $130 million worth of CapEx spend. More than half of that is going to be earmarked for the construction and development of the
de novo facilities, as Dr. Berger mentioned. We opened up two facilities in the first quarter, one in Maryland, one in California, and
we&rsquo;ve got 12 other facilities that are in various stages of construction and completion, that should open up by year end. Most of
these centers cost on average $5 million to $6 million to build, so if you&rsquo;re talking about 12 centers at $6 million, we&rsquo;re
talking about $70 million of CapEx spend just on those de novo facilities, which is more than half of our spend this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have shifted a fair bit of our CapEx and we
are spending extraordinarily right now to accelerate growth, which we expect to start seeing some contribution from these centers in the
latter half of this year and into 2025. It&rsquo;s been a strategic &hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome, congrats again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;m sorry, Brian, did you say something?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oh, sorry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, no problem. We have had a strategic change
or strategic shift in our thinking around CapEx because of the opportunity that exists to accelerate growth due to the fact that there
is just significant volumes out there, heavy volumes that today we&rsquo;re not able to avail ourselves of, either because we&rsquo;ve
got capacity constraints in some of these markets or we just simply don&rsquo;t have access points that can service patient populations
that currently today we&rsquo;re not servicing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right, got it. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Brian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question comes from John Ransom from
Raymond James. Please go ahead with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning. This is an obvious question,
but when you guys have a 100 basis point mix shift to higher cost scans, does that pretty much drop to the bottom line?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, it does, John. Are you talking about our
margin improvement, John?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, yes. It was 120 basis points, but&mdash;okay.
Yes, but it &hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, that was hypothetically. Every 100 BPs&mdash;I
was saying hypothetically, every 100 BPs is 100 BPs (inaudible) as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think a substantial portion of that, probably
80% of it, in that range, drops down to the bottom line, which is one of the reasons why we&rsquo;re very focused on reporting that this
year, more so than prior years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I know you&rsquo;ve talked about this, but it
seems like that&rsquo;s just a structural trend that will go out into the future, this mix shift?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I believe so, I believe so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, okay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, last year I think it was contributed by the
improvement in reimbursement and shift of higher profit margin business, the advanced imaging. I think in subsequent quarters and years,
it will be impacted by the implementation of our new DeepHealth operating system and automation of what have been up to this point largely
manual processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, and just two others from me. As we think
about the cadence of the year for AI eRAD, is that still on track to be&mdash;is there any acceleration in that profitability curve or
is it still on&mdash;is that part of your $5 million or is it still on&mdash;is most of the $5 million in the core imaging sector?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think we expect some acceleration on two
fronts. One is further implementation and adoption of our EBCD program, which we&rsquo;re very pleased with and I think has provided some
outstanding results, one of which I&rsquo;ll mention and that was released, interestingly, this morning from the Cancer Moonshot White
House program, is that we have detected 450 cancers so far with the use of this breast screening tool that might have otherwise gone undetected,
so the notion of enhanced or earlier breast cancer detection is a reality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we get further implementation on the west coast,
which is continuing to ramp up, and as we continue to improve, I think, the patient adoption of this, we could alter our guidance on that
perhaps later or in subsequent quarters. Also, some other initiatives that we&rsquo;re starting, one of which is what we&rsquo;re calling
EPS, or enhanced prostate screening, is something that we&rsquo;re now rolling out as a self-pay opportunity for men to come in at a fairly
nominal price, get an MRI scan with artificial intelligence, even if they&rsquo;re asymptomatic and are just looking for greater confidence
than routine blood tests that are used primarily for prostate screening. We expect that to be something that probably will become more
apparent in our financial results towards the end of the year. We&rsquo;ve had some very good results and some testing sampling that we&rsquo;ve
done, much like in breast screening, finding early cancers that are certainly going to lead to better outcomes for men who choose this
pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, and the last one from me, just on M&amp;A,
I know you don&rsquo;t put future M&amp;A in your guide, but if we&rsquo;re spitballing and we&rsquo;re six months down the road, should
we expect the probability of just more tuck-in deals in existing markets, or what are the odds, do you think, you&rsquo;ll wrestle one
of these elephants to the ground? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. I think tuck-ins will be a continual part
of our acquisition and growth opportunity. We find those to be very targeted in our existing markets, if you will, and both on the east
coast and west coast, there&rsquo;s a constant pipeline of requests that we&rsquo;re getting for further opportunities in our existing
markets. Much like we demonstrated in Houston, when we entered that market just this quarter, April 1, if there&rsquo;s other markets
where we can find a good platform company to build a longer term presence in a market, we would look at those. Those may become a little
bit more expensive than the tuck-in acquisitions, but they do represent a longer term platform to expand our reach. I think you can continue
to see those along with the de novos as being a very important component of this year&rsquo;s growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thanks so much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks John.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question comes from Andrew Mok from Barclays.
Please go ahead with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, good morning. Wanted to follow up on the digital
health segment and the DeepHealth capability. One, can you help us understand what the adoption rate is for the EBCD AI option, and then
would love to hear more on the cost savings and throughput efficiencies that this could drive in imaging centers. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, good morning, Andrew. As I mentioned, I
think in my remarks, on the east coast, where we&rsquo;ve had the longest experience with EBCD, our current adoption is about 40% of all
of the patients that are offered EBCD, that actually enroll and pay $40 for that procedure. We have found that to be consistent with our
expectations and believe, though, that we can drive that number higher. We&rsquo;re hoping that, at least on the east coast and perhaps
even by the second half of this year, that number could approach 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the west coast, the adoption rate is in the
32%, 33% range, but that is also very comforting to us because that&rsquo;s higher than what we started off with on the west coast &hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">East coast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;m sorry, on the east coast, and the west
coast has learned some of the tools. But I have to caution everybody that this is an educational process. It&rsquo;s not something that
we simply ask somebody to sign up for without giving them a lot of the background and benefits of these tools. As we learn more and more
about what the issues are and questions that our patients have for these procedures, the more, I think, effective we are in communicating
that benefit and the more receptive our patients are.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would tell you it is my firm belief that artificial
intelligence as it relates to breast screening and mammography is state of the art and will be the routine sometime in the future, and
we expect there to be some form of reimbursement for it; but during this period, we want our patients to benefit from the investments
that we&rsquo;ve made and the opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would also like to include that not only do
we detect the breast cancers more accurately and earlier, we&rsquo;re also having an impact on recall rates, so that fewer of our patients,
when some sort of further diagnostic work is necessary is being determined, artificial intelligence is giving greater confidence that
some of these call-backs in fact just need to be watched and don&rsquo;t need to go through further diagnostic work-ups, such as biopsies
and other procedures. The benefit here is substantial in both regards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In terms of our radiologists, I think we&rsquo;re
comfortable feeling that our radiologists are more accurate and confident now as they get more and more use of artificial intelligence,
and we think we can get perhaps as much as a 15% to 20% improvement in their productivity simply because the majority of the breast screenings
that we do are normal scans, and they have a greater confidence level when the artificial intelligence confirms their initial impression
of the mammogram being normal. I think there&rsquo;s a win-win-win for everybody in this remarkable new achievement, for which we are
continuing to evolve further tools not only in breast but, as we mentioned, in lung and prostate, where we expect similar results and
benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d also like to again mention the fact
that we&rsquo;re going to embark on an accelerated program for cardiovascular screening for which artificial intelligence tools have now
been approved for reimbursement, that give further benefit to our patients rather than just doing the CT scan itself. I think all of this
will be part of our DeepHealth operating platform and I think you can look forward to us talking about other AI tools that we will expand
into, to help improve both diagnostic accuracy and productivity for our radiologists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thanks for the color. Then secondly, I
think your other category in your payor mix ticked up about 100 basis points sequentially. Just want to clarify what that other category
is and what&rsquo;s behind that uptick. Is that tied to the higher EBCD volumes as well? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, it&rsquo;s everything that isn&rsquo;t just
patient scanning, so it&rsquo;s management fees, it&rsquo;s the category that doesn&rsquo;t fit into MRI, CT, X-ray, ultrasound and mammography
procedures, such as certain interventional procedures, and part of it had to do with when we&mdash;the reason why it shifted, I think
about 1% quarter-over-quarter, had to do with when we re-jiggered our operating segments between the imaging center and the digital health
segment and moving that eRAD business out of the imaging center segment, changed the proportions of those exams, but nothing fundamentally
has changed with our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I was actually talking about the other category,
the payor mix, not the procedure mix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oh, I&rsquo;m sorry. I thought you were talking
about the procedure mix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, that would be from EBCD, because that&rsquo;s
self-pay, so it&rsquo;s in the other category.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, that&rsquo;s likely the case, Andrew. I&rsquo;ll
double check &hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it, okay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&hellip; and follow up with you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, that makes sense. Then are there any metrics
you can share to give us a sense of the backlog or unmet demand? I think it&rsquo;s clear that there&rsquo;s strong demand backdrop and
you have this patient backlog, but just curious if there&rsquo;s anything you can share with us or give us a sense of that unmet demand.
Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think that the backlogs are a function of, number
one, more use of imaging and a greater adoption of it, aging population, a growing population, all of which require more and more imaging,
and I think greater than previously determined shift away from hospitals. I think there is more effort on the part of payors to direct
the business away from hospitals, again by education and giving the patients an alternative that they might not have previously realized
were available to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think this is important and has become more
important as deductibles have risen with some of the newer products. When you stop to think about how much, if a patient goes to a hospital,
they have to pay for, their co-pay segment of a scan, these numbers are rather substantial and eat through their deductible very quickly,
and their effective use of that cash can go further for more health services if they elect to go to an outpatient facility, where as we&rsquo;ve
talked about in the past, the scanning differential can be three to five, or even more times in a hospital. I think all of these are coming
together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think perhaps the other reason is that things
that were more esoteric in the past are now becoming more familiar and patients are more comfortable with them, things like PET CT scanning,
maybe in the past people thought was only done at veterinary clinics, but particularly as things like prostate screening and now for Alzheimer&rsquo;s
screening, as well as the general use of it in cancer for diagnostic staging, are now just being recognized by everybody of the enormous
value that these tools are, so there&rsquo;s greater adoption and greater demand for this coming from all sectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would say that also, our experience for increased
demand is not unique to RadNet. I think almost all of the people that we talk to in the industry, other large chain operators as well
as acquisitions when we talk to our various opportunities here, are all experiencing increase in demand. What makes RadNet a little bit
different is that our ability to take advantage of this by deploying capital, either by doing acquisitions or building de novo centers,
allows us to address these kind of opportunities, which benefit not only our patients and referring physicians, but our communities as
a whole. I just think that right now, imaging is enjoying a very important role in delivery of healthcare, and as I&rsquo;ve said previously,
I believe it is the gateway for population health and I believe normal people are coming to agree with that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, and specifically to your question, Andrew,
from the standpoint of what KPIs we look at in order to determine how big our backlogs are and whether we have to invest in those centers
to expand them or build new centers, we particularly look at advanced imaging and how long it takes when a patient calls into our scheduling
department, how long it takes them to actually come in and get their exam performed. For advanced imaging, if someone&rsquo;s calling
up for an MRI or a PET CT and is concerned that they have a serious injury or serious disease process, if we can&rsquo;t get that patient
in, in a matter of three or four days, we&rsquo;re going to end up losing some of that business because the patient is not going to wait
around a week or two to figure out if he or she has cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manage those&mdash;that scheduling, we try
to, as much as we can, load balance with our scheduling departments that are centralized in that region and we&rsquo;ll try to direct
that patient to another center that might have a scanning slot that&rsquo;s open with less waiting time, but unfortunately what we&rsquo;re
facing right now are some real scheduling difficulties, which is why we&rsquo;ve determined that we need to build new centers and increase
capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The newer equipment, particularly in the areas
of MRI have faster throughput these days, better post-processing software, so we are able to do more scanning in the same amount of work
hours, and we&rsquo;ve been, as much as we can over the last couple of years, trying to upgrade our MRI scanners to the newer technologies,
but this is&mdash;it&rsquo;s the highest class problem we can have, but it&rsquo;s still a problem nonetheless, because we don&rsquo;t
want to lose this patient volume to our competitors. Referral patterns, physician relationships tend to be sticky, and so when you lose
business to someone else, it&rsquo;s hard to get that business back, which is why we&rsquo;re trying to expand our capacity so quickly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew Mok</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thanks for all the color. Appreciate it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question comes from Yuan Zhi from B.
Riley Securities. Please go ahead with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Yuan Zhi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning. Congrats on a great quarter and
thank you for taking our questions. I have a couple.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, if we take a step back, you have different
market shares in different states. I&rsquo;m curious, what was the reason to have higher market share in some states and the lower market
share in others? Either way, was it because of lack of good acquisition targets or do you think you&rsquo;ve reached certain critical
mass in those states, say here in Texas or even new states, if you are expanding further, what would be the criteria or goal there?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, good morning, Yuan. When we look at a market,
we don&rsquo;t necessarily have a market share in mind. We have found in our operating history that there are tremendous benefits to operating
at scale in local markets, most of which are around centralizing a lot of the business processes that we perform on behalf of our centers.
For instance, we have the centralization of scheduling, pre-authorization, insurance verification, revenue cycle, marketing, among other
things, and so when we think about building scale in a regional market, it&rsquo;s not necessarily driving towards a particular market
share. It is really the result of how we can grow the business profitably using the benefits of scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When we look at all of our markets, we want to
have that benefit or we want to be able to achieve those benefits of scale, and there isn&rsquo;t necessarily a magic market share where
we can do that. When you look at where our sites are today, we certainly don&rsquo;t have a lot of scale in the State of Florida - all
four of our centers are in one particular market there in the Treasure Coast - the Port St. Lucie, Stuart area of Florida, but that&rsquo;s
a state where we would love to expand given the right opportunity. Arizona, we feel like we&rsquo;re not yet getting the benefits of the
scale that we could possibly have in the Phoenix area, and we did make an acquisition there with our partner, Dignity Health, where we
acquired seven additional centers this quarter, as Dr. Berger mentioned in his prepared remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think the short answer to your question is we&rsquo;d
like scale in all of the markets that we have because of the ability to manage these business processes more efficiently and get better
profitability from our assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Yuan Zhi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it, that&rsquo;s very helpful. Maybe one additional
housekeeping question here - great to see the increase of PET CT volumes related to PSMA. I&rsquo;m curious, did you guys see any uptake
on Alzheimer&rsquo;s related procedures, both the PET CT part as well as the MRI part, in Q1 or recently in April?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, we are starting to see more volume come in,
in the Alzheimer&rsquo;s area, both on the initial PET CT screen for the presence of these amyloid plaques, as well as some ongoing MRI
monitoring once these patients are on these therapies, although we&rsquo;re not seeing a lot of that because these patients are just starting
to go onto these therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been a delay in qualifying a lot of
these patients onto some of the newer drug therapies and getting the initial diagnostic imaging approved to qualify these patients. The
decision for this was passed down to the individual regional Medicare administrators, or what we call the Macs, and that has caused a
delay; but we are starting to see some uptake, but we&rsquo;re talking about patients in the hundreds of patients not the thousands or
tens of thousands of patients that you would expect&mdash;that we would have expected to see by now. We still remain optimistic that this
is going to happen. I think these therapies proved to be efficacious in their clinical trials. It&rsquo;s going to lean heavily on advanced
imaging, both on the initial PET CT screen to determine whether these patients are eligible for these therapies, as well as the ongoing
MRIs that are indicated every three to four months for at least 18 months when these patients go on these therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think this is just another example that give
us encouragement and optimism about the continued use of advanced imaging. Dr. Berger mentioned cardiac imaging, which in growing in popularity,
the PSMA test on the PET CT side, Alzheimer&rsquo;s, and there&rsquo;s others that are coming down the road, particularly in the area
of PET CT where there is a lot of development of some of these new radioactive tracers that are targeting very specific solid tumors,
cancer tumors in the body. I think it&rsquo;s going to be an ongoing process that unfolds here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Yuan Zhi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thank you. That&rsquo;s all from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Yuan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question comes from Jim Sidoti with Sidoti
&amp; Company. Please go ahead with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, thanks for taking the questions. I know it&rsquo;s
been a long call. Just two quick ones for me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Can you update us on how things are going in Texas?
I know it&rsquo;s been a while since you entered a new market. How do you find this market? Is it easy to get paid, and is it easy to
do business there?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, well, it&rsquo;s a little hard to say now.
We completed the first acquisition of seven centers&mdash;we completed that on April 1, so we don&rsquo;t have a whole lot of operating
experience there as of yet. I think the integration of that business and what we call the RadNet-ization is just at the very beginning
stages. The other acquisition that we&rsquo;ve announced of the American Health imaging centers in Houston, that&rsquo;s scheduled to
close in the June-July timeframe, and we anticipate some further integration of those two operations to create a platform from which we
can grow at that point.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think we&rsquo;ll have a lot better feeling
of and a better way of answering your questions in the coming quarters, but early indication is that this is a very attractive market,
good demographics, good payor relationships. We think that we&rsquo;ve identified and partnered with an excellent group of radiologists
and they&rsquo;re motivated, as are we, to really grow that platform through further acquisitions, de novo centers. There&rsquo;s a number
of hospital relationships in that market that could be interesting to us as we continue to grow there, so I think we&rsquo;re highly encouraged
from what we see so far.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, all right. Second one, can you just give
us updated share counts, what we should be using for Q2 and Q3 this year?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Could you repeat that? Sorry, it was a little
difficult to hear you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_071.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sorry, it was a question on what&rsquo;s the right
share count for the rest of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, so we have somewhere in the 73 million to
74 million outstanding shares. We typically wouldn&rsquo;t&mdash; unless we&rsquo;re doing any acquisitions using our stock for the remainder
of the year, we don&rsquo;t expect that share count to go up significantly. Generally speaking, it&rsquo;s the first quarter where we
issue equity to our existing employee base as part of their annual compensation, so that was already completed in the first quarter, so
I wouldn&rsquo;t expect anything to increase our shares materially between now and the end of the year, unless there&rsquo;s some acquisition
where we choose to use stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Jim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and gentlemen, at this time, I am showing
no additional questions. I&rsquo;d like to turn the floor back over to Management for any closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right, thank you, Operator. Again, I would
like to take this opportunity to thank all of our shareholders for their continued support and the employees of RadNet for their dedication
and hard work. Management will continue its endeavor to be a market leader that provides great services with an appropriate return on
investment for all stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your time today, and I look forward
to our next call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and gentlemen, with that, we&rsquo;ll be
concluding today&rsquo;s conference call and presentation. We thank you for joining. You may now disconnect your lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rdnt-20240508.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa2NCaPty552qYkxvmRwfanq/yUrGobphS/144JGkQoJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:RDNT="http://radnet.com/20240508" elementFormDefault="qualified" targetNamespace="http://radnet.com/20240508">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://radnet.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20240508_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20240508_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rdnt-20240508_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rdnt-20240508_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://radnet.com/role/Cover" xlink:href="rdnt-20240508.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://radnet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #B @\# 2(  A$! Q$!_\0
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M/!7@I/ NG?88;R]NK&,@6Z7,AEDMU'1 Y^9@. -V6XY)ZUOT %%%% !1110
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MZ+ZG^M>N_#OX,Q^+-3^U7BG[#"V2,?ZT^G^)KVN&.'3+)458X88$& /E5 *
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M<\-:M9ZQI=XH:*>VD#J?8^A]0:\A^//_  2\^!W[0ADFUCP#HMGJDF2NH:9
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M8/\ A]I_B;QY>7-GIVIWRZ=;B"$S2/*4=\8';:C<U\TK_P ''_[.)_YBFO\
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M&\2VCJI^5[Z4*\Q/;*J43V*M7T[_ ,$H/@&OBBZ;7[Z'=I^CX"!AQ+,>0/\
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MG_!)<;O^"C_P9!Z?\)79?^C!7@?B7_D/WG_7>3_T(U[Y_P $E_\ E)!\&?\
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M#1#IR.V/2NH\&>-])^(?AVVU;0]2LM6TV[4-%=6LHEBD'L10!L4444 %%%%
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M'_HA:M?"S.3?,EZGHG_!8/\ :)\:_!'XB^#[7PKXBU#18+[3II)TMWVK*RR
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M?PQ>:1I64ZI$"QZ*NJ7:J/P4 ?A7SC_P6J^*5QXI_:4T_P -+)_H/AG38V*
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M;KA?K7V-_P %^/\ E*E\2/\ =T__ -(8*^.;/_CY3ZU^4Q_Y'"_Q_JC^S/\
MFAO^Y?\ ]L1^F'_!>S]G'^S/@G^SO\5+.W_=ZKX0T_0-1D Z/':)+ 3[LIE'
MT45^9L3[&#5_1=^WM^S=_P -,_\ !$JTTV"W\[5M#\%Z7K^G;4W-YMK:Q2E5
M_P!IHQ(G_ Z_G/!YKJXFHRP^/]O#K9KU1XOA+F$,TX=E@:^OL[P:_NM77YV^
M1_1__P &_?[3'_#0/_!/C0].NKCSM7\ SMH%R"<MY2?/;M]/*95!_P"F9K[C
M'6OP-_X-E_VFO^%9?M<ZO\/[RY$>G_$+3L6Z$\&]MMTD>/3=$TP]\+7[Y U^
MB87$*O1C675)G\PYWELLOQ]7!3WA)KY='\T<Y\6?'-O\-?AAXB\0WC!+30]-
MN+^9L]$BB9S^BU_(IXV\5W'CKQIJVN7C;[S6;V:]G8_Q/)(SL?S:OZ5/^"X_
MQ@'P:_X)H?$BXCF,-WKMDFAVV.K&YD6-Q_W[,GY5_,N1S7PO&6(YJL**Z)O[
MS^@_ K >SP>)QTOM227I%7?Y_@>]?\$Z_P!M0_L#_M&6OQ"CT"'Q'<V5C<6D
M-O+*8U1IEV%\^R[A^-?H ?\ @ZPUG/\ R2W3O_ YZ^3?^">G_!&/QQ_P4.^%
M.J>+]!U[1]#T[3=2.EXO8W9II$C21B,=@)%%>^_\0LWQ2/\ S/GA7_P&D_QK
M/#_VY3IJ%-/E2LMCMS.7A]BL5/$8N:=23;EJ]]CX&_;#_:#C_:G_ &D_%GQ"
MCTB+0F\578O7LHW\Q8G\M0Y!]W4M^-;7_!/;XQ-\!OVU?AGXJ\[[/#I/B&T:
MY?TMWD$<WYQLX_&NV_X*/?\ !+_Q9_P3;U'PO#XDUC3=:C\51W#V\ME&R+&8
M2@93N/7]XOZU\UZ9<M:WD<B-M96R".Q!R*X,MJ5L/F<'77O.5G\SZ;B3#X+-
M.$:L,N:E34/<_P"W.WGH?V,12B959>5QP?6H=9/_ !*[C_KDW\J\W_8J^+*_
M'3]DOX=>+1(LDFO:!9W$[ _\M3$HD_)PP_"O2-:_Y!EQ_P!<F_E7ZG+8_CFC
M\:]3^//Q+_R'[S_KO)_Z$:]\_P""2_\ RD@^#/\ V-=E_P"ABO _$G_(>O?^
MN[_^A&O?/^"2P_XV0_!G_L:[+_T.OS'AW_D9KUD?V!XG?\DE4](_FC^I9#_*
MOS]_X.4?B4O@K_@F]>:7D>9XJUVQT]1GLC-<-_Z( _&OT =L*.:_"W_@YZ_:
MQM?B-\<?"WPMTF[6XM_!<4FH:KY;Y5;R< (C=MR1C/MYN.M?;9[B%1P4F^JM
M]Y_.OAME4\=Q!AXQ6D7S/R4=?SL?EHGWJ_67_@U3^'WV[XZ?$[Q,T)*Z7H5M
MI\<F.C3SER,^X@'Z5^32_,WK7] W_!M!\ YOAE^PYJ/BN[A,=UX\UI[F$E<%
MK6W40QD>Q<2FOF^#,.W4G6Z))?-GZ]X[9@HX/#8);N3E\DK?J?HWG*5^"O[1
MO_)P'C?_ +#M[_Z/>OWJ(PE?@K^T;_R<!XW_ .P[>_\ H]Z^^/YG+'_!-[_E
M,#\'_P#KPU/_ -(KFOW(\>>#;/XA^"]4T+4(_-L=6M9+2=2/O(Z%3^AX]Z_#
M?_@F]_RF!^#_ /UX:G_Z17-?O!'T_"JET]#*'Q,_ 'XL?#R[^%_Q%U[PQJ4?
M^DZ+>2V4H(^_L8KN^C#!^E<[96B:?:10Q_+'"@C0>@4 "OM/_@M)\#_^$(^/
M&F>,;6';9^+K4+.RCY1<PX4Y]VC,?X@U\85)J=-^P/\ \I@_@3_O7_\ Z175
M?ONW]*_ C]@?_E,'\"?]Z_\ _2*ZK]]V_I5U.AG3Z^I\'?\ !=O_ ))OX!_[
M"EQ_Z*6OS1E_U9K]+O\ @NW_ ,DW\ _]A2X_]%+7YHR_ZLU$=S0_07_@V<_Y
M,O\ &W_8\7G_ *3VU?H[7YQ_\&S8S^Q?XV_['B\_])[:OT<JJGQ&='X$%%&:
M,U)H%?C'_P %3O\ D^CQM_OVW_I+%7[.5^,?_!4[_D^CQM_OVW_I+%0!\??M
M._\ )%]4_P!Z'_T:E?T.?LH_\FQ?#O\ [%K3O_26.OYX_P!IW_DB^J?[T/\
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M\ZCS(V]"5/S*17M6: ,W0->35[90W[NZ11YL).&0UI9K@OC3\.-2\3:3]O\
M#MXVF^(;,;K>53A9?]A_4&OGK0_^"HEE\)O&#>%_BYI-UX;U&!MC7Z1$PMC^
M-EZX/JN10!]A9I'^X?I7-?#7XO>&?B_H*ZEX9U[2M<LW /FV=PL@3/9@"2I]
MC@UTCM\K?2@#^:7_ (+[<?\ !5#XD9_NZ?\ ^D,%?'EI_P ?4?UK],/^"S'_
M  3F^-GQY_X*)^.O%/A'X>:YKF@ZFME]GO+?R_+FV6<2-C+ \,I'2OF33/\
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MZC@=Q7[*L/Y5=3H9T^OJ?!O_  7;/_%M_ /_ &$[C_T4M?FC)]PU^K'_  6
M^!/B[XY>!_!EMX3T.\UJXT_4)YKA8,9C5HU4$Y([U\&_\.^?C-_T(.L?^0__
M (JH-#H/^"8_[<<7_!/;X+:YX3FT*3Q$^L:[-K(N$G\CR_,CC39C!Z>7USWK
MZ3_X?M6W_0@S?^!X_P#B:^3?^'?'QF_Z$/6/_'/\:3_AWS\9O^A!UC_R'_\
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M10 ;?:F^6OI3J* &K$%%.(R*** &^4*/*%.HH ;Y0H5-M.HH **** "BBB@
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M4+75M%UBUCO+*\MI!)#=0NH975@>00: -JBBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_068.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_068.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '] L,# 2(  A$! Q$!_\0
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M ,\)/^^#71T4^4/:,YS[-/\ \\)/^^#1]FG_ .>$G_?!KHJ*.0/:,YW[-/\
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M4"&T4M)3 2BEI*!"8I*=2$4 )24M%,0VBEI* $I,4ZDH$-I*?28IB&TE.I*
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M!R2:\0^ _C/B7PG>R<C=-8EC^+Q_S8?\"K8^.?C'^R=!3P]:28N]1&9]IY2
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M N:6FTN:0Q:6DHH 6EI**!CJ6FTM(!:*2EH&+1244 +1110 M%)2TAA1113
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M (5U7A[XF:#JOA+^W+Z^@LQ$PCND8,!%(<D("1\YP/X<]Z5T-Q9VM%<]X?\
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MOPDT#1M1L-8M[O4FN(,2JLDD90G'<! <<^M5K'_DX34O^P:/Y1UZ6H"J H
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M5(&0.3P/4T6'S'G/P+_Y 6N_]A1__05JO\;[./4;SPA8S,RQ7-^T+E#A@&*
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M_'''#&L<2*D:C"JHP /0"BS'=;G@NNZUX6O?@1IVD6$MI+JQCMXXK2)09EN
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M7(Z$=C3Z2EID!1113 6BDI:0!1110 9I:2B@!:***!A2TE% A:***!A1110
M4E+10 E%%% @I*6B@8E%%% @HHHH 2BEI*8!1112 2BEI*8!24M% A**6B@#
MF1UJ2H^].JJ.S,\7\2'4M-S2UN<8M%)2TABYI:;2@T .HI*6@8M%)2TAB@TM
M-I<T#'4M-I:!BTM-I:0#@:6FT9H&.I<TE%(8ZEIN:6@8ZBDHI .I0:;2T#'9
MI:;FE!I#%I:2B@8ZES3:6@!U+3,T[-(8M+3:6@!:6FTM Q:7-)12 =12 TM
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MEH&+FEIM+2 =124M PI:2B@!:*** %HI*7-(84444P%HI**0"T444 %+244
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M /'V_P :/[#T[_GW_P#'V_QH]M$/JD^Z./HKL/[$T[_GW_\ 'V_QH_L33O\
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MT0_82.>I:Z#^S+/_ )X_^/'_ !H_LRT_YX_^/'_&CVB#V$C !IV:W?[-M/\
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IT<R'[-F?16C]FA_N?J:/LT/]S]31S(/9LSJ*T?LT/]S]311S(/9L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_071.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_071.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C L@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W/4)9(DA$
M4A0O)M) !.-I/<>U5/-N?^?N7_OE/_B:GU<[8K<_]-O_ &5JS_.]ZUBM#EJ2
MM)EGS;G_ )_)?^^4_P#B:/-N?^?N7_OE/_B:X:3QKJB:=JFJKHMH^FZ=<3Q2
MM]O83,D+E694\K;G"D@;_;-='<:_I5I+;PW6I6EO+<X\B.:94:3/ V@D$]:8
MKLUO-N?^?N7_ +Y3_P")H\VY_P"?N7_OE/\ XFN;\0^+K#0+9P\]M+? (R61
MN%21U9@N0.3@<GIV-0V'C*&\U36M.>U:&XTTLT>7R+A% RP..,$@$<XRI[T!
MJ=5YMS_S^2_]\I_\31YMS_S^2_\ ?*?_ !-8-MXHTUM)TN]O[NUL&U&%)8HI
M[A5)+*#M4G&XC<!P*DM/$NG7NOW^BPS*;VR1'E7<O(;/0 YXXSD#&X>M 79M
M>9<_\_DO_?*?_$T>9<_\_DO_ 'RG_P 36-KNN?V+90W/D>=YMU!;;=^W'F2*
MF[.#TW9QWQ4B^(=';41IRZK8F^8D"V%PGF$C.1MSGC!_(T!=FKYES_S^2?\
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M/<Q @8;<%"-\T9QDCY^O!J[I>MWL^L3:3J>GPVEVENMRAM[DSQLA8K]XHA#
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MPG*3P3@I^ZC9S@@$'E"O7C\,4706EW-K[9?_ //TW_?"_P"%'VV__P"?IO\
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MZ@MI97$<=W90A$B:V0%U+,R3N<N2,C;L.W)Z@%C78?:8_P#GHG_?0H^TQ_\
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M"\DRG*'<=JXB7E\'Y^G%6--L=4O;#4Q=6UYI^LZA$!/J-PL+(!T$<:1S%E4
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M?"U_[\K_ (4?V5IW_/A:_P#?E?\ "BBB["R#^RM._P"?"U_[\K_A1_96G?\
M/A:_]^5_PHHHNPL@_LK3O^?"U_[\K_A1_96G?\^%K_WY7_"BBB["R#^RM._Y
M\+7_ +\K_A1_96G?\^%K_P!^5_PHHHNPL@_LK3O^?"U_[\K_ (4?V5IW_/A:
M_P#?E?\ "BBB["R#^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PHHHNPL@_LK3
MO^?"U_[\K_A1_96G?\^%K_WY7_"BBB["R#^RM._Y\+7_ +\K_A1_96G?\^%K
M_P!^5_PHHHNPL@_LK3O^?"U_[\K_ (4?V5IW_/A:_P#?E?\ "BBB["R#^RM.
M_P"?"U_[\K_A1_96G?\ /A:_]^5_PHHHNPL@_LK3O^?"U_[\K_A1_96G?\^%
MK_WY7_"BBB["R#^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PHHHNPL@_LK3O^
M?"U_[\K_ (4?V5IW_/A:_P#?E?\ "BBB["R#^RM._P"?"U_[\K_A1_96G?\
M/A:_]^5_PHHHNPL@_LK3O^?"U_[\K_A1_96G?\^%K_WY7_"BBB["R#^RM._Y
M\+7_ +\K_A1_96G?\^%K_P!^5_PHHHNPL@_LK3O^?"U_[\K_ (4?V5IW_/A:
M_P#?E?\ "BBB["R#^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PHHHNPL@_LK3
MO^?"U_[\K_A1_96G?\^%K_WY7_"BBB["R#^RM._Y\+7_ +\K_A1_96G?\^%K
M_P!^5_PHHHNPL@_LK3O^?"U_[\K_ (4?V5IW_/A:_P#?E?\ "BBB["R#^RM.
M_P"?"U_[\K_A1_96G?\ /A:_]^5_PHHHNPL@_LK3O^?"U_[\K_A1_96G?\^%
MK_WY7_"BBB["R#^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PHHHNPL@_LK3O^
M?"U_[\K_ (4?V5IW_/A:_P#?E?\ "BBB["R#^RM._P"?"U_[\K_A1_96G?\
M/A:_]^5_PHHHNPL@_LK3O^?"U_[\K_A1_96G?\^%K_WY7_"BBB["R#^RM._Y
M\+7_ +\K_A1_96G?\^%K_P!^5_PHHHNPL@_LK3O^?"U_[\K_ (4?V5IW_/A:
M_P#?E?\ "BBB["R#^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PHHHNPL@_LK3
MO^?"U_[\K_A1_96G?\^%K_WY7_"BBB["R#^RM._Y\+7_ +\K_A1_96G?\^%K
A_P!^5_PHHHNPLB6"TMK7=]GMXHMWWO+0+GZXHHHI#/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140531309208784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  08,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RadNet,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000790526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3326724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1510 Cotner Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los
  Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">445-2800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RDNT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %N7JE@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !;EZI8.)F3 ?     K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NLTV!%'7"]-.("$Q"<0M<KPMHFFCQ*C=V].&K1."!^ 8^\_G
MSY(K] J[0,^A\Q384KP97--&A7XMCLQ> 40\DM,Q'Q/MV-QWP6D>G^$ 7N.'
M/A#(HK@%1ZR-9@T3,/,S4=25086!-'?AC#<XX_UG:!+,(%!#CEJ.4.8EB'J:
MZ$]#4\$5,,&8@HO?!3(S,57_Q*8.B'-RB'9.]7V?]XN4&W<HX>WI\26MF]DV
MLFZ1QE_1*CYY6HO+Y-?%PV:W%;4LY#(K5EE9[*14JSNUO'^?7'_X785=9^S>
M_F/CBV!=P:^[J+\ 4$L#!!0    ( %N7JEB97)PC$ 8  )PG   3    >&PO
M=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$
M[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4
M\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4
MR]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C
M 1-702:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6
M:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+
MTHMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3
M:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@
M %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ W
MQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYK
ME']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;V
MD:4E,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?
MR"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:
M/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#Q
MK9P\'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-
MZ#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB
M&38:<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.
MBY 1OQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR
M- >CFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"
MP#E_+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,I
MV#F?P.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4W
MBA*>0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F
M.$KTL<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1
MN0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/
MPT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,K
MD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;
M\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\
MX^;'<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;Z
MEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10
M[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%
M(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^
M)F!+PWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#
M7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1
M/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO
M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( %N7JEB7BKL<P
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MCEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( %N7JE@D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 6Y>J6#B9DP'P    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M6Y>J6)E<G",0!@  G"<  !,              ( !S@$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !;EZI8TFA094($  !R$   &
M    @($/"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M6Y>J6)^@&_"Q @  X@P   T              ( !APP  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " !;EZI8EXJ[',     3 @  "P              @ %C
M#P  7W)E;',O+G)E;'-02P$"% ,4    " !;EZI8JL0B%C,!   B @  #P
M            @ %,$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 6Y>J
M6"0>FZ*M    ^ $  !H              ( !K!$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ 6Y>J6&60>9(9 0  SP,  !,
M         ( !D1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  VQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="radnet_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://radnet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="radnet_8k.htm">radnet_8k.htm</File>
    <File>rdnt-20240508.xsd</File>
    <File>rdnt-20240508_lab.xml</File>
    <File>rdnt-20240508_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "radnet_8k.htm": {
   "nsprefix": "RDNT",
   "nsuri": "http://radnet.com/20240508",
   "dts": {
    "inline": {
     "local": [
      "radnet_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rdnt-20240508.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rdnt-20240508_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdnt-20240508_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://radnet.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-05-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "radnet_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-05-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "radnet_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001683168-24-003246-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-24-003246-xbrl.zip
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M4QON'VA+:%HJ_M<_"@)_?&(E.N @#4IE+\EA+?BJ0WT HH+##,('W/UZ TM
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M#P[*"7E7HY@J!9H/:,_! 7^,JA<M)&2Y- R<K<IL,2#;J]@K5,S/@-N0Z<C
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M1T7F,!TS'$>>3XEZ!4A,!X@(_17>&(9.(&$'NL='*-\,SYTO0PO/PR-Y[A2
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M9;%XV,GWS.$,X:%P*;$&:=URY3, !M\11R)0?8!>=0E9-=R+V+/<@MSZ\9'
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MXJ%<_@[*Y9>*+[Y>_LL]E[E?R+Q!7E!'@IO.V=7E6?>B2_8 &@I?V^WK:.?
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MZSYAVJVE5CXE!U^T6@6U1$2R02OIVZ"IL#.PM57K(040LDE$3P7M=7+3TY%
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M7UFI-Q+%S%\,[ZE7$A2ZO[P':)0/AUS#BME38HTPH^Q/?*.6&_;35.:$57;
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MXVM$/U&4CZ?(CB3!;7ZC=ZOLDY"FBU-UC\1ZK[I,;AZ#799 $NP@N**-F,3
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M-%39KADRB\FG5%)769*B2E2+HDIDMZ;FRUHDX@((,1 !Q2.3J%^_?H[[?02
MI#B]*Y$=RAFK%A- W+A/O_XX?OS+;UZ_^.ZO)[,OOWEV\97\-\/_^_+U\]??
M/?OKEW_6_\JW?[:OOWSR\JM_9J]>__.[9__VR;*I^[]DYW>W??:ZW+@N^]Y=
M9S\VF[R>ZP?S[)5KR^4G\J \^H-_;I.WJ[+^2W;WD[]^^>2OS]ZNR\NRSS[_
M_.S>EW]^(F_]X9V__U-]V6V_^/_ZR]Z][4_SJES)KQ>N[EW[1:9/G_;-5EH(
M?UXV?=]L?)M?/G_Q]^S5CT__[9-RDZ_<_W/WT6=G/V]7GV07W[W^MT\^\<VO
M7;E:R^0\O/M@^_:+[+HL^O5?LL=W[V[?2C/_O_;HMQCE;9NW;?[1VARU]C].
M3[.O2U<5?\E^D&/^A0BR7P97+YS(N^STU 3EEU\]_\^QZ-%7/-KV!R_A9Y=-
M6[@V?/:DRA=OLG.1GUU3E85TH\\O*R?=KJIM7A1EO?JW3^Y^PK^[;;[P?W?]
MKG+_]HFUMFBJ*M]VTC7_KR!PSN_>_?2+#'+ZM"O_Y518XS6M;^/*M7VYR"L_
M8]+_+[)T"BNWY!.%?\*:OG__TT_^^J?_>?[HKJQ#7QS[Q8-/QTWI:DACR>SZ
M>?TB>[W;2@<OVORR7'R1?9]OG,[]]\T7V<MM7S9U]Y?LF[(H7(T5L"V0-/5G
MWQ:^OJE/]_?ZU$).CP?RY[[%_\%*R']EB8^L]F7K\C>GEV[9M-+-+;?(>^P
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MJK++Z/R>B(2,@D*N/>  %8B47>5M"9$FXG6EAZJ0JT+62-T % %)2!J"*$'
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M'YF%'*R^HC=/C[\%W;0C=^52G*86"B+4*?0;/8IVV0U=(96H]06-6%]>'DX
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MLJ2IQ_R .E!Z7E; //:NZQ,>!@8MQJ5W#F>/&2(^+5[3*>"\V)O/P$IESHW
MTR96Z!;57^J0-H)B)37';T(RD*@J;6:16JE)C4C+4>%FHFPFC-.W02<.ONJ-
MZ*M#]9K#]48*1\%:F<1?TE$/#\^>C)NCFTHE0$(S+R?#W!F_'"I >1:/"HC@
M/I!8>?:LL&M X;A8-TWG+"XDIW!]/25_X]3=+DHU2;H.YWTN\T#@\>)/LN6^
MN)C[:H $@Z:I/MNA]R1M]EMLO9V7L<ZB2,NQ4-R6_:5*.^.Z2+XKWX(7LE_[
M:":+I.9@,2%7"GA9XMEU=DK5/2.'C!U73I%A\>94^E(X%-R0?P2^-4MBHHR]
M]IN?B5U%051SY(*:)T$R$0+7T%]0DJMV),PQHDE4P<UKS0!#.RLFC_UM<MQ-
M$U707R) $HFV==\<*8J#6U"N.JX\R>L6OPREE:1*.+^2VY47#:2N,>'H/4-)
MW\-C;=5\1FR 87=:B4QT0X^J%AVRRGQR9$]FU*/L" 6U2EV:(4J;:T8?<@NW
MY=8!#X"# M;6>'6F)U"ZU?M+V.MR<4Q&K)1VF5AP]/DL>Q$N()2IB939'":4
M^)ZD0EH"+J,!Z\Q8T#;,#0P=/3 V7<A]7F7G<],DDK&I F9OASJI=<&8:,AI
MS_5&!5\6ZT$NK :@YT9"]=*F!J<4RJ2R:#3]0JPWINU2?S16;%%/E)^M 3?Y
M:ZXIV'L]_:N50CV9@=*'4@B2JN[ ZQE*ZGC!E&P?"[:3F;I %3SM2+_?/3\,
M5+)^NR6W+@G>\\4Z;F!?7LRKS*Q(IAS+Z&^.%J-59.1,2?6N7#>H:-FRY%9.
M+.6I-NJ?L BZ[:<CY:9\XQM%'<KPRDF=SII-]&92!4)S<:8QHBF]Y;WB/?=O
MXST?(MYS_S;>\U&>J(\RWO,Q")/;_/??)O_]HBY::?R%:.[\^TG>+JI\UYV=
MS/Y(F>]Q&J:S[M^4^WGO/XFY8K6NR?D-H)@9S$6Y0H'2DYE5).C<*B#E\'V"
M1P,5CGJ4&(.;TYJ"5;5VU1;<^ @$M8R+)15O?=B!Y#]EI(%F3.[B>:9?1XYR
M,5?-J-3"S&OG"X\T'O0#[VV.LLR=/<42 G"YN27\[7*E!1)BVF4:YBA:J];J
M$4/&YCH],O&)JOVO"))/M_;<Y)A6R8H$V//L.:(B!M3<['R!K'GJ)_)^H;VR
MZ19\H ,83H:NI[>B+:DI41AB[\ZUIKR2,L5MCA FL7@/-"<E1ZT%BW+XNC0Q
MM- LE_3T:(/Z\<+J';D:D2HMA)+OLCL/[MK9T1B,UBB)I%Y+$G,E89LC)8Y'
MM1)]?3EBUO%R'"*?F:6^(CTQ_*0>-I=@.B9F-@G5M*SNXH,O<[B!*I?'>HUQ
MHG4D&DZ4CB $9FA8JSIQP*(\'[W:8I4HUY,OUMG#NY].Y,"^/(@ 'Y><GG3Z
M_KU/Y]#+?8Z3NLB49YX%6NBGDKM^Z?.3&DAG3W$VRE4Q##2=<!9YU=@L O;+
MI>V<_0Y.+]7RQ22IJIZ%PS>1HS+=N^V )?7(1>5U,AQ$'^0 . F%2FO#)OF(
M.H [HMD\&5 %@Q<$BVPIHSU39B^;8I?H2$J+A$)(N16%LV2!$7L]B09'>  &
M'HWL,._>\%MMNB&!HR^L!4F">W%57EGEF W=^ '>C:))&B&TB\FJH(9XH@U)
M$34<\[C\G$?!!]VS[#HQ6#)?Z,I;+W;_LF"(OY'M"FWM5>%^M3P0-)_@:D3-
M!&+IROGJFF7M2SEB]EAQ"J_PE;+\PK&[K5NX+1\>]2"?3/GAPZHKO)I$"UN6
M[48UCJ77@3Q"!K53(T0&49<2I?L .V+\^ "9QE7/-QM W[;K'8$_A+/XHJ&M
M10 M7*D!<X7(< >7BNI)\R^MODD21V]= H+)&&1BD#!-*L*V*7LM.R-[1G=W
MR6K$95-HG"RO]S9<?Z2.FI:NL]II!Q5D-WGAPDY*@ZG3VC748'R=W;)>5$/A
M55!?5;)HN$J*&U39D0(*?57*A2CGK.K(63/LX;C@#U^VIBT)Z:=I6IK<S4JX
M>+Z;6RJWK)2[UE*QZ5(2K^>,$5:$-P6:#Q!;,5P@NJX;43%D6]0.4C5ON64U
MM(B1M)N2ALL-H#$6$5+1>8@ ,T$\YJ3% $XA5*DYDF270>3:.<,NR;;L%VLK
MK)FB5_Q/5HTWKF\:T.FPQ?P@O(U :=EL.S&]11(C!MM;>IV)4M;6#KO>E]E.
M4_R!SD(PWZK2361G3^DM[Q7;>7 ;V_D0L9T'M[&=C_)$W<9V/JQB41,EU/E[
MN\V+DN77NWZ4@)(4=#/?"27-TKF(+=Y_GLK_2-NP>G9Z,VL=,BUUO2-&?%PO
MVU(O;L*)ZS4:2]&K4P[->%0^*G#;W9MGYP\_S5AQ[--L+PE>7E_R)BY0=.\*
MF%"SV*)3" KFSTUK>-%$J0HJ=U1* <;*":=O-UH]'% MTTUWGC;WB)Y2H:ZA
MXMQ,1S^JZ_ )+)EV7#,)*HX*%7U1J-3ZZ"V C6E2VJ,$M;B'^;N6TV?_H]X>
M+6%.4]F9IYA+CWS\?+&&?U1Y7$.M9;/[L%/2! UWU52P(TU7HL$:U=:(/1=+
MP6K0IRYK^;X:0NEK!>='[W3(C[+Z]@D:'D7HU5B>B,;DG2%[U@#+_81T*E\Z
M8M]4 E33X_3=YA*./0)1DR(4A4^9BD6]CQ3@3I;[IHVJ*\S]+B<=ZX#B?EL>
M/BWO.3(5S:&]*I--XO7AOAD;B-+/X)FEWEXTON+NT]>:9"(+[JIEW.RP6,Q_
M+C:)V;T^Z1Z-'R67".C)-.?-@R4)[91OZ7-3/_(>YS%[>?'<IF)4C5VQF+3L
MF[G&\JJMETVJZ2?FA$K0Q<[O_RBK,(_[DG<B.WVB(>@QK#*6N:V:EE9@;3$?
M)#R&2!TA!KJ?%BA"T[2[D#2QS7=(K2G?9K)5WFA96ZO1.B9G%X-24]-*Y1/\
M%D>'[A?X/^5\2_^\AS#O]UY'_@H?ODXJ=JY+'UH;MGB_'#D?7B[54L;P+);"
MP+:O2F.\@]/+>?B] R;R2C^VW_YE1OD>=@"UA"0%KNRBKP0/,;^+69:0RQJ8
M1G'AV()T1/1X=1>ZO=:5M<4V/-L'U7Q\ VX'4L6]^/'Y7(3_//M?IVTN)T?N
M_S;O@L<\\89*AQ(/MG?/6"*;9AQ?Z37J_?SV4XTVZXT!)XVFN8FZQT"@)2@8
M/4LD2R17(OA;M(!OT*J]1_[\4Y^U<"J2OST-*0S'VY=63W\N5RN&QBD4(A.2
MPE.Z4&9>V912/$?PD1JT)5-D"_CZ(K1ETUR%U00M3N!]8EJH*9=[[=KS<ZN7
M5?@\*R.FM$@%<@G<VWQCN0NB_7'?+&65<F;]5D@?1=C&-^.C\Z$/TY$24[S;
MGC-_/\ TQNH0??.C.V7.0N7Q IO3(+"MH^<.'T]GS:<92D?5P[T8K2K>\([W
MFI'F8@'YE)%KHNL\T4#\/S7F"S.&\:A+2_]5B-8Q$ UN%F40V+_U+;PX%@C3
MV0'3/.EA X1EA/^AVIF>UKD(.HPD+V :&!B86+O%F^GAHZ9XD?^=E1<G100[
MI;>\5ZCQX6VH\4.$&A_>AAH_RA-U&VK\T!?E-'4BK\_0=Q)SB'QFV$1NSXGJ
M.=&BV>1O'!SDM=)T(%:E%#]&];QQ?5LN4,;$PC_=.E<$)$-6@[*EU;'D.^!E
M5;,"8]!0R]/@-LE!\1.)VH,6O0!DUP..TZALU[<-07 ;XGZE299*9>B(Z65$
M+Q-1:5Y6>ZUZV!@<6PPMR[D>4*'(L-0!-QX2=^[ @NU'AP97?S*@LY/9U!SX
M$S7?8^#?0."V5PP&#C_LPF@0YY99=#)3DK@$D>$]O[ERY1B0(:50A.&@O]DV
MVZ'*+8F1K"\'GVI<5D/)(!@J VK$(T'LA0;Y\(/P+[8Z0HXEBP& #7A1JV:0
M7^<[=5.L&["(Y0#*CS 066FP6+=<$J-:6TJ:^OKIGB0JN9#.:5#=1:?XD?;G
M%HZ_W,6D :5["@#_!-Q>*\EDG?<AHXQ0$645A4>4ISP9(VE _^4(R,9,7>5E
M17U<HVV;B9S$N$B:@Q'IA7*FQ'5CAL7DZTZV 6/D,BF&06C+SAGW9)H+4A.V
M;"%UV1@_^2+77>]+4A,^0(_E6JYV8(I(*Y4'D;MJ%(>?AQV@CNU=2"Y!DJ)L
MK;F!=A8-.35]T 4P)T;'Y@9/UK.GQ]*P#BD46"';?< ?:Z-QQ)KD)D=)3O?.
MCHW^)B9G#(DT7^3=6N%338!>D*T19R+D/K=7Y<+Y6V0'!KM%[X'0#<N&#[V?
MD:68@$B&]A =AGH3ZLE1Y:C2'S>?W><#A7+>F .JHT8'F:O0.L[ILD1JIN*4
M+-NEYYXC$9=?B2,($,PPN2M!4XITE&;E,.:)G1J/@XM>5@M(EC'].P6N>;GK
MND:D4;E(U\40;==ZX$@YAY\N\XTL<]Y::#1FZ^C7*530DX=MYO9>12[]\.RU
MA^S4*N,W^>[2C=Z]=<VV<B&<@ B3I3K4#CFU5Y#X98VL@455UJ*DJ?(#^5T2
MM\3TJ]%[#PE>.08,D05!JG_)>=FX-O%C1TY4 RX8>#%;N=JADIF_'[FCC;\9
MC24X'GGG2INP^:2"IO \N5J:50VQSGLC@.],4#G ]T3\G\RN\FJ(]X1/_D*3
MEHV1ZG@'][.R#NJ'IE8J!H5< )O K(WCHF5#IJ+8^2R:+C<H04Y:9J4E#$GL
MS%BJ%RT9R$]F-D6E8A6'NOQ%":5_S(OO79]*%Y9CB4(F;EM%?4'D:=J.Y3,5
MTB\F,_)LLAH1PMX@2C2ZE0"1$1'>C;C_ AK MXI!7.6JYX^)%[$;=+_E"CO3
M@6*=_3 S4IY2EY?[+]A".L3 4)A=HK!?$,E!C)#6TMA4<5_*LUH;JH=S*+"G
M0S/;5@W+E"YRO24S5RK.;V<(OM$8FU8)%S4+B)2#GI8"EQH,[8Z@.[E]B@+H
M5SL/;TIE3QY-A.>V]YC" #T=9QK6X%*6$3)5;;O>=4 V>K)%LAIH+B/G-D<V
M#PB-*X>=X'DHO8K=F@)W/0]*L\R$JW_663@@36RE'5V+JN17*,3%ZW>16PH>
M=L3SF/?6Y661*(;DW/65]DI;(A%0<MBO<V.V#KJWO]E5J?9/&6S9-F^\)A5C
MBJO7)#FK)$G#T& F(B!NW_*;Q"$>W<8A/D0<XM%M'.*C/%&W<8@/[=Z;9ASB
MGQZCVFW= AD9"L%KQO1T'J Q9\T@S:TG+9D6Q?1U,__]A^=*)6'TU=!*(3OI
M!?,>-OI#+LN5 C1'OD3BQ&E5AX([U'V1Q*\J,+"@ILV1;=K(J<E]X34_9AEY
ME0\-C4PZW[?]0J3J'9*ND;4:Z2-49ZDR1Z<-IJ=3[#"ZWR'9>]!B*J*HRGL4
MSWK8#GL(;<BC'$,-%%A6KO>NEK?Y!C8XTD><*-9?-^U!3^E'@C=*+-D8"\BM
MIHN1@UCI%/S+F\MFD2P:V)BU9T-/\\LZ9S[_^N<!BF0;/BG*CCJ_,9C,M= "
M[-4 JM9!L"@EYPI9*G//;ZY%/9;FAP'?.Z:OR'?=_(8\HYH9"573$:0<?&_@
M /$^U#35SB^0F5RAG>L<]D=N+"CR+O<&KT?Y3WJ#5D 1-EHY8LV>=4@\ )B8
MMOA$E-2?G 'F]0P%O#GT\;"'>5AZ)&T@NRC)A-25GLMJY @G57G@;1L?@BR>
M@5&UE[IOU?4<JIVV;N7="F'Y*Y1UWXT]YG$[J;O0@'\*']^OHI5''V!7-?T8
M<B;FL3ER*^P=[ MND7)CA%]#O:3=IP07^T631/!1,8SF&<?&C0G'^F@62I F
M#E5J0+(.TVY$/Y+$'+RY'Y@D]N68'EZSO$]F((Y<3(>IY'5PJ2.4LU49.I+:
MI4]O=;">11) N"G%4-[I7@B4E6K.JVRQ<D+;INM/37:I/%GVU][U98Q#/A12
M-.J'#'O)WMWE*+RP$4&B%U[3OCF9K>4 V 6:+BVR%H^<H RY&FRL4A*J >8R
MZO>RP#6VOV>7VZY:L-/@?/D26+5K0^$7G:W>+=8U\_<<G!M*6\>HAZ_W.\Z)
M83X57BRO9P4^&?+&]PVS:45T^B22C+3#//RVECM'6JIX!WCYR_3E<!&<S'QR
M6.6K-84SK$E<WO6$<@^N+^DLS'ZD_X253[!D<)X$1XK2%L&]LR[AF\;E8"1"
M2![;F0;3Z&V-. Q>C0FQFP+,67IA9JX"WC09XMH2,</]%>\744YN.K^M2U8K
M*9'A3R9Z8[&4B1S2B6(Y#A,KX?%,DBLOMENYC4I21D[%9_7'8^?^YR!BY'^O
M2^/F/CN9_5A6HOF^<@"ZX*8^R_Y(--U^/J:S_'\?$70_%>M+]G='I@(-7?F,
M2<5!\<#SKF @*W^C%2SC6A/O87JEWM036?VORQ8Q<[7@-/ B]ZC;VGT7 &(A
M:./+;BG2BZ'R&-"A.[\[2U*Y##DV-QW:XIT61NX;;=Q2N].&60B5E&]L,A8-
M;*[#+T]FX:<T!;J_9<\T&G2-9*%K93GTBHEH5G3]RG_)<9W64=.R:(P7I77X
MDC)\5TX+7HE*[O-\%Q 5"W K;J!!!9>$]GC.(*%B@^KLM=CR74 :0)?WO[)Z
M:[E6[;*BQP:A\+/F,Z5X$<E;97ES8NN:O-)@[=^FL1MOWW+[EFF\Y;W"6H]O
MPUH?(JSU^#:L]5&>J-NPUH<V!*89UCI6V 0FCT%UDQA5J+ZJ#,@CSEZE%49Y
M=[,#]M7534GTTZA@B-6LC0PKZ[+K Q&-I8;0?0043-&PD(0QL\,QYI\[F=$Y
MGRNZIVKD7_;^#M#ZKH\(>+HO-<01G.V*%4K9X+U;R_R@+G*+6< )MM*E\T5#
MZ,VR>CXGLZ\)<$/,;^'F,3JW3MS[N4?RIQ&%;>M.\T&TY-9^@)!0-[0,(5QA
M0<N%?=Y"41ZDP=VB0O8 QZJXQPUB:53XE=IJU8U=?H'14;'! 0 6IB^WB$.8
MPY$+$!&C=+51I45=>\CHZ!C_\\[HL2$"*O^,'(<:-Z6A QI!HK":ZT QV<J_
M]U=!EESNCETV=![>GU+TL^\3,3D/#IT"'K'%PI;VI.Y] S(?G]/@@7=-F_R
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M(M1[!TNRRS[+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UTJI>B>@5HI9X1*ZM
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M#GS=V WNW;3%-^Z7>_^JW?(_4$L! A0#%     @ 6Y>J6##;$ >O%   %9L
M  T              ( !     ')A9&YE=%\X:RYH=&U02P$"% ,4    " !;
MEZI8QQ>>Z)Y"  #SGP( $0              @ ':%   <F%D;F5T7V5X.3DP
M,2YH=&U02P$"% ,4    " !;EZI8&9#;+R=<  #+#P( $0
M@ &G5P  <F%D;F5T7V5X.3DP,BYH=&U02P$"% ,4    " !;EZI8'4RV/"<#
M  #="P  $0              @ ']LP  <F1N="TR,#(T,#4P."YX<V102P$"
M% ,4    " !;EZI8[+7_*/X*  " A@  %0              @ %3MP  <F1N
M="TR,#(T,#4P.%]L86(N>&UL4$L! A0#%     @ 6Y>J6'S4'VA4!P  T5<
M !4              ( !A,(  ')D;G0M,C R-# U,#A?<')E+GAM;%!+!08
1    !@ & 'X!   +R@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>radnet_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdnt-20240508.xsd" xlink:type="simple"/>
    <context id="AsOf2024-05-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000790526</identifier>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-05-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-05-08" id="Fact000004">0000790526</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-05-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-05-08" id="Fact000010">2024-05-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-05-08" id="Fact000011">RadNet, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-05-08" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-05-08" id="Fact000013">001-33307</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-05-08" id="Fact000014">13-3326724</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-05-08" id="Fact000015">1510 Cotner Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-05-08" id="Fact000016">Los   Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-05-08" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-05-08" id="Fact000018">90025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-05-08" id="Fact000019">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-05-08" id="Fact000020">445-2800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-05-08" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-05-08" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-05-08" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-05-08" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-05-08" id="Fact000025">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-05-08" id="Fact000026">RDNT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-05-08" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-05-08" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
